+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cell Encapsulation: Focus on Therapeutics and Technologies, 2019-2030

  • ID: 4770787
  • Report
  • Region: Global
  • 501 Pages
  • Roots Analysis
1 of 5

FEATURED COMPANIES

  • 24Haymarket
  • Caladrius Biosciences
  • Eutilex
  • Kadimastem
  • OhioHealth
  • StemBios Technologies
  • MORE

Overview

Chronic disorders, such as diabetes, cancer, heart disease, obesity, and certain types of mental health problems, are considered among the leading causes of death and disability across the globe. According to a report published by the Center for Managing Chronic Disease at the University of Michigan in 2018, more than 50% of the global population lives with some form of chronic illness. In 2018, the global prevalence of diabetes (considered to be one of the fastest-growing clinical conditions) was estimated to be around 425 million; likewise, around 450 million people worldwide are suffering from some form of mental health problem and/or neurological disorder. In addition, the World Health Organization (WHO) reported that different forms of cancers account for about 0.6 million deaths annually in the US alone. Over the years, advances in cell biology and regenerative medicine have led to the development of various cell-based therapies, which claim to possess the potential to address several unmet needs related to the treatment of different chronic clinical conditions. However, there are certain evident challenges, such as scarcity of viable donors, inherent immunogenicity, complications related to supply of oxygen / essential nutrients to grafted cells, drug delivery limitations, and the need for frequent re-administration of cells, which have so far restricted the use of cell-based interventions.

Extensive research on cell encapsulation strategies has enabled the development of a variety of technologies capable of confining therapeutic entities within biocompatible matrices/carriers. Encapsulated therapy products offer a myriad of advantages, and have been shown to be capable of addressing existing concerns related to cell sourcing, obviating the need for complex surgical procedures, and enabling targeted drug delivery without the need for immunosuppressive follow-on regimens. In fact, since 2013, over 3,000 patents have been published related to the aforementioned type of therapy, indicating the rapid pace of R&D activities in this domain. Stakeholders have also received significant support from both private and public investors. However, the commercial success of such products is still dependent on ongoing clinical studies, as no such therapy has yet been approved.

Scope of the Report

The ‘Cell Encapsulation: Focus on Therapeutics and Technologies, 2019-2030’ report features an extensive study of the current market landscape and the future potential of encapsulated cell therapies and affiliated technologies. It is worth mentioning that the study also provides insights on therapy products wherein other active drug substances have been encapsulated within living cells. Amongst other elements, the report features:

  • A detailed assessment of the current market landscape of encapsulated cell therapies and affiliated technologies, highlighting various target disease indications, phase of development, encapsulation method, type of cells / API, and route of administration, along with information on various stakeholder companies that are developing novel encapsulation methods / techniques for use in storage and transportation of cells, as well as other applications.
  • Comprehensive profiles of industry players that are currently engaged in the preclinical / clinical development of their proprietary encapsulated cell therapies, featuring an overview of the company, its financial information (if available), and a detailed description of its product(s), highlighting mechanism of action, current development status, and key preclinical / clinical trial results. Each profile also includes a list of recent developments, highlighting the key milestones achieved, partnership activity, and the likely strategies that may be adopted by these players to fuel growth in the foreseeable future.
  • An in-depth analysis of the patents that have been published related to cell encapsulation technologies, since 2013. The analysis also highlights the key trends associated with these patents, across patent type, regional applicability, CPC classification, emerging focus areas, leading industry players (in terms of the number of patents filed/granted), and current intellectual property-related benchmarks and valuation.
  • A comprehensive clinical trial analysis of completed, ongoing and planned studies of various encapsulated cell therapies. The analysis highlights the key trends associated with these clinical studies across various parameters, such as trial start year, trial status, phase of development, leading industry and non-industry players (in terms of number of trials conducted), study design, target therapeutic area, key indications, study focus, clinical endpoints, and enrolled patient population and regional distribution of trials.
  • An analysis of the partnerships that have been established in the domain in the period 2013-2018, covering R&D collaborations, licensing agreements, mergers and acquisitions, product development and/or commercialization agreements, manufacturing agreements, clinical trial agreements, process development agreements, and other relevant deals.
  • An analysis of the investments made at various stages of development, such as seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings received by companies that are focused in this area. The report also features a detailed study on the various grants that have been awarded to research institutes in this field.
  • An analysis highlighting potential strategic partners (for instance, manufacturers) for encapsulated therapy developers based on multiple parameters, such as therapeutic focus overlap, cell type overlap, research programs, existing collaborations, and developer strength

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on likely licensing deal structures and agreements that are expected to be signed in the foreseen future, we have provided an informed estimate on the likely evolution of the market for the period 2019-2030. In addition, we have provided information on (potential) sales-based revenues generated by encapsulated cell therapies that are currently in late stages of development for the treatment of different chronic disorders, based on parameters, such as target consumer segments, likely adoption rates, and expected pricing. The report features likely distribution of the current and forecasted opportunity across [A] different therapeutic areas (eye disorders, metabolic disorders, neurological disorders, and oncological disorders), [B] target disease indications (ataxia telangiectasia, breast cancer, diabetes, glaucoma, head and neck cancer, macular telangiectasia, pancreatic cancer, Parkinson's disease, and retinitis pigmentosa), [C] type of encapsulation material used (alginate-based microcapsules, cellulose hydrogels, medical-grade plastics, and red blood cells), and [D] key geographical regions (North America, Europe and Asia Pacific). To account for the uncertainties associated with the development of novel therapeutic products and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD unless otherwise specified.

READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 24Haymarket
  • Caladrius Biosciences
  • Eutilex
  • Kadimastem
  • OhioHealth
  • StemBios Technologies
  • MORE

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Context and Background
3.2. An Overview of Cell Therapies
3.2.1. Cell Therapy Manufacturing
3.2.2. Supply Chain
3.2.3. Key Challenges
3.3. An Introduction to Cell Encapsulation
3.3.1. Historical Overview
3.3.2. Cell Encapsulation Approaches
3.3.3. Encapsulation Materials
3.3.4. Advantages and Challenges
3.4. Potential Applications of Cell Encapsulation
3.4.1. Targeted Drug / Therapy Delivery
3.4.2. Immunoprotection
3.4.3. Storage and Transportation
3.5. Key Growth Drivers and Road-blocks

4. CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Encapsulated Cell Therapies and Encapsulation Technologies: Developer Landscape
4.2.1. Distribution by Year of Establishment
4.2.2. Distribution by Geographical Location
4.2.3. Distribution by Size of Developers
4.2.4. Distribution by Type of Offering
4.3. Encapsulated Cell Therapies and Encapsulation Technologies: Development Pipeline
4.3.1. Distribution by Target Therapeutic Area
4.3.2. Distribution by Phase of Development
4.3.3. Distribution by Type of Cells and Other Encapsulated Components
4.3.4. Distribution by Type of Encapsulation Material Used
4.3.5. Distribution by Route of Administration
4.3.6. Distribution by Application Areas
4.5. Encapsulated Cell Therapies and Encapsulation Technologies: Initiatives of Big Pharmaceutical Players

5. ENCAPSULATED CELL THERAPIES AND ENCAPSULATION TECHNOLOGIES FOR METABOLIC DISORDERS: COMPANY PROFILES
5.1. Chapter Overview
5.2. Developers with Clinical Candidates
5.2.1. Beta-O2 Technologies
5.2.1.1. Company Overview
5.2.1.2. Financial Information
5.2.1.3. Product Description: ꞵAir Bio-artificial Pancreas
5.2.1.4. Recent Developments and Future Outlook
5.2.2. Diatranz Otsuka
5.2.2.1. Company Overview
5.2.2.2. Financial Information
5.2.2.3. Product Description: DIABECELL®
5.2.2.4. Recent Developments and Future Outlook
5.2.3. Sernova
5.2.3.1. Company Overview
5.2.3.2. Financial Information
5.2.3.3. Product Description: Cell Pouch System™
5.2.3.4. Recent Developments and Future Outlook
5.2.4. ViaCyte
5.2.4.1. Company Overview
5.2.4.2. Financial Information
5.2.4.3. Product Description: PEC-Direct™ and PEC-Encap™
5.2.4.4. Recent Developments and Future Outlook
5.3. Developers with Preclinical Candidates
5.3.1. Company 1
5.3.2. Company 2
5.3.3. Betalin Therapeutics
5.3.4. Company 4
5.3.5. Defymed
5.3.6. Company 6
5.3.7. Company 7
5.3.8. Kadimastem
5.3.9. Company 9
5.3.10. Seraxis
5.3.11. Company 11
5.3.12. Company 12

6. ENCAPSULATED CELL THERAPIES AND ENCAPSULATION TECHNOLOGIES FOR NON-METABOLIC DISORDERS: COMPANY PROFILES
6.1. Chapter Overview
6.2. Developers with Clinical Candidates
6.2.1. Azellon Cell Therapeutics
6.2.1.1. Company Overview
6.2.1.2. Financial Information
6.2.1.3. Product Description: Cell Bandage
6.2.1.4. Recent Developments and Future Outlook
6.2.2. EryDel
6.2.2.1. Company Overview
6.2.2.2. Financial Information
6.2.2.3. Product Description: EryDex System
6.2.2.4. Recent Developments and Future Outlook
6.2.3. Erytech Pharma
6.2.3.1. Company Overview
6.2.3.2. Financial Information
6.2.3.3. Product Description: GRASPA®
6.2.3.4. Recent Developments and Future Outlook
6.2.4. Gloriana Therapeutics
6.2.4.1. Company Overview
6.2.4.2. Financial Information
6.2.4.3. Product Description: EC-NGF
6.2.4.4. Recent Developments and Future Outlook
6.2.5. Living Cell Technologies
6.2.5.1. Company Overview
6.2.5.2. Financial Information
6.2.5.3. Product Description: NTCELL®
6.2.5.4. Recent Developments and Future Outlook
6.2.6. MaxiVAX
6.2.6.1. Company Overview
6.2.6.2. Financial Information
6.2.6.3. Product Description: MVX-ONCO-1
6.2.6.4. Recent Developments and Future Outlook
6.2.7. Neurotech Pharmaceuticals
6.2.7.1. Company Overview
6.2.7.2. Financial Information
6.2.7.3. Product Description: NT-501
6.2.7.4. Recent Developments and Future Outlook
6.2.8. PharmaCyte Biotech
6.2.8.1. Company Overview
6.2.8.2. Financial Information
6.2.8.3. Product Description: Cell-in-a-Box®
6.2.8.4. Recent Developments and Future Outlook
6.3. Developers with Preclinical Candidates
6.3.1. Company 1
6.3.2. Sernova
6.3.3. Company 3

7. PATENT ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Encapsulated Cell Therapies and Encapsulation Technologies: Patent Analysis
7.3.1. Analysis by Publication Year
7.3.2. Analysis by Geographical Location
7.3.3. Analysis by CPC Classifications
7.3.4. Emerging Focus Areas
7.3.5. Leading Players: Analysis by Number of Patents
7.4. Encapsulated Cell Therapies and Encapsulation Technologies: Patent Benchmarking Analysis (Industry Players)
7.4.1. Analysis by Patent Characteristics
7.4.2. Analysis by Geographical Location
7.5. Encapsulated Cell Therapies and Encapsulation Technologies: Patent Valuation Analysis
7.6. Leading Patents: Analysis by Number of Citations

8. CLINICAL TRIAL ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Encapsulated Cell Therapies and Encapsulation Technologies: List of Clinical Trials
8.3.1. Analysis by Trial Registration Year
8.3.2. Geographical Analysis by Number of Clinical Trials
8.3.3. Geographical Analysis by Enrolled Patient Population
8.3.4. Analysis by Phase of Development
8.3.5. Analysis by Study Design
8.3.6. Analysis by Type of Sponsor / Collaborator
8.3.7. Most Active Players: Analysis by Number of Registered Trials
8.3.8. Analysis by Trial Focus
8.3.9. Analysis by Therapeutic Area
8.3.10. Analysis by Clinical Endpoints

9. RECENT PARTNERSHIPS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Encapsulated Cell Therapies and Encapsulation Technologies: Recent Collaborations and Partnerships
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Therapeutic Area
9.3.4. Analysis by Type of Cells and Other Encapsulated Components
9.3.5. Most Active Players: Analysis by Number of Partnerships
9.3.6. Analysis by Regions
9.3.6.1. Most Active Players
9.3.6.2. Intercontinental and Intracontinental Agreements

10. FUNDING AND INVESTMENT ANALYSIS
10.1. Chapter Overview
10.2. Types of Funding
10.3. Encapsulated Cell Therapies and Encapsulation Technologies: Recent Funding Instances
10.3.1. Analysis by Number of Funding Instances
10.3.2. Analysis by Amount Invested
10.3.3. Analysis by Type of Funding
10.3.4. Analysis by Number of Funding Instances and Amount Invested across Different Indications
10.3.5. Analysis by Amount Invested across Different Type of Cells and Other Encapsulated Components
10.3.6. Most Active Players: Analysis by Amount Invested
10.3.7. Most Active Investors: Analysis by Number of Instances
10.3.8. Geographical Analysis of Amount Invested
10.4. Concluding Remarks

11. GRANT ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Encapsulated Cell Therapies and Encapsulation Technologies: List of Academic Grants
11.3.1. Analysis by Project Start Year
11.3.2. Analysis by Focus Area
11.3.3. Analysis by Support Period
11.3.4. Analysis by Type of Grant
11.3.5. Analysis by Amount Awarded
11.3.6. Analysis by Study Section
11.3.7. Analysis by Therapeutic Area
11.3.8. Analysis by Type of Cells and Other Encapsulated Components
11.3.9. Analysis by Type of Encapsulation Material
11.3.10. Leading Funding Institutes: Analysis by Number of Grants
11.3.11. Leading Recipient Organizations: Analysis by Number of Grants

12. POTENTIAL STRATEGIC PARTNERS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Potential Strategic Partners for Cell Therapy Development
12.3.1. Opportunities in North America
12.3.1.1. Most Likely Partners for Cell Therapy Development
12.3.1.2. Likely Partners for Cell Therapy Development
12.3.1.3. Less Likely Partners for Cell Therapy Development
12.3.2. Opportunities in Europe
12.3.2.1. Most Likely Partners for Cell Therapy Development
12.3.2.2. Likely Partners for Cell Therapy Development
12.3.2.3. Less Likely Partners for Cell Therapy Development
12.3.3. Opportunities in Asia-Pacific and Rest of the World
12.3.3.1. Most Likely Partners for Cell Therapy Development
12.3.3.2. Likely Partners for Cell Therapy Development
12.3.3.3. Less Likely Partners for Cell Therapy Development
12.4. Potential Strategic Partners for Cell Therapy Manufacturing
12.4.1. Opportunities in North America
12.4.1.1. Most Likely Partners for Cell Therapy Manufacturing
12.4.1.2. Likely Partners for Cell Therapy Manufacturing
12.4.1.3. Less Likely Partners for Cell Therapy Manufacturing
12.4.2. Opportunities in Europe
12.4.2.1. Most Likely Partners for Cell Therapy Manufacturing
12.4.2.2. Likely Partners for Cell Therapy Manufacturing
12.4.2.3. Less Likely Partners for Cell Therapy Manufacturing
12.4.3. Opportunities in Asia-Pacific and Rest of the World
12.4.3.1. Most Likely Partners for Cell Therapy Manufacturing
12.4.3.2. Likely Partners for Cell Therapy Manufacturing
12.4.3.3. Less Likely Partners for Cell Therapy Manufacturing

13. MARKET FORECAST
13.1. Chapter Overview
13.2. Forecast Methodology and Key Assumptions
13.3. Overall Cell Encapsulation Technologies Market, 2019-2030
13.3.1. Cell Encapsulation Technologies Market by Upfront Payments, 2019-2030
13.3.2. Cell Encapsulation Technologies Market by Milestone Payments, 2019-2030
13.4. Overall Encapsulated Cell Therapies Market, till 2030
13.4.1. Encapsulated Cell Therapies Market: Distribution by Therapeutic Area
13.4.1.1. Encapsulated Cell Therapies Market for Eye Disorders, until 2030
13.4.1.2. Encapsulated Cell Therapies Market for Metabolic Disorders, till 2030
13.4.1.3. Encapsulated Cell Therapies Market for Neurological Disorders, till 2030
13.4.1.4. Encapsulated Cell Therapies Market for Oncological Disorders, till 2030
13.4.2. Encapsulated Cell Therapies Market: Distribution by Type of Encapsulation Material Used
13.4.2.1. Encapsulated Cell Therapies Market for Alginate-based Microcapsules, till 2030
13.4.2.2. Encapsulated Cell Therapies Market for Cellulose Hydrogels, till 2030
13.4.2.3. Encapsulated Cell Therapies Market for Medical-grade Plastics, till 2030
13.4.2.4. Encapsulated Cell Therapies Market for Red Blood Cells, till 2030
13.4.3. Encapsulated Cell Therapies Market: Distribution by Geography
13.4.3.1. Encapsulated Cell Therapies Market in North America, till 2030
13.4.3.2. Encapsulated Cell Therapies Market in Europe, till 2030
13.4.3.3. Encapsulated Cell Therapies Market in Asia-Pacific, till 2030
13.5. Encapsulated Cell Therapies for Eye Disorders: Distribution by Indication
13.5.1. Encapsulated Cell Therapies Market for Eye Disorders: Macular Telangiectasia, till 2030
13.5.1.1. NT-501 (Neurotech Pharmaceuticals)
13.5.1.1.1. Target Patient Population
13.5.1.1.2. Sales Forecast
13.5.1.1.3. Geographical Distribution of Projected Opportunity
13.5.1.1.3.1. Projected Opportunity in the US
13.5.1.1.3.2. Projected Opportunity in EU5
13.5.1.1.3.3. Projected Opportunity in Rest of Europe
13.5.1.1.3.4. Projected Opportunity in Australia
13.5.2. Encapsulated Cell Therapies Market for Eye Disorders: Glaucoma, until 2030
13.5.2.1. NT-501 (Neurotech Pharmaceuticals)
13.5.2.1.1. Target Patient Population
13.5.2.1.2. Sales Forecast
13.5.2.1.3. Geographical Distribution of Projected Opportunity
13.5.2.1.3.1. Projected Opportunity in the US
13.5.2.1.3.2. Projected Opportunity in EU5
13.5.2.1.3.3. Projected Opportunity in Rest of Europe
13.5.2.1.3.4. Projected Opportunity in Australia
13.5.3. Encapsulated Cell Therapies Market for Eye Disorders: Retinitis Pigmentosa, till 2030
13.5.3.1. NT-501 (Neurotech Pharmaceuticals)
13.5.3.1.1. Target Patient Population
13.5.3.1.2. Sales Forecast
13.5.3.1.3. Geographical Distribution of Projected Opportunity
13.5.3.1.3.1. Projected Opportunity in the US
13.5.3.1.3.2. Projected Opportunity in EU5
13.5.3.1.3.3. Projected Opportunity in Rest of Europe
13.5.3.1.3.4. Projected Opportunity in Australia
13.6. Encapsulated Cell Therapies for Metabolic Disorders: Distribution by Indication
13.6.1. Encapsulated Cell Therapies Market for Metabolic Disorders: Type 1 Diabetes, until 2030
13.6.1.1. DIABECELL® (Diatranz Otsuka)
13.6.1.1.1. Target Patient Population
13.6.1.1.2. Sales Forecast
13.6.1.1.3. Geographical Distribution of Projected Opportunity
13.6.1.1.3.1. Projected Opportunity in the US
13.6.1.1.3.2. Projected Opportunity in Japan
13.6.1.1.3.3. Projected Opportunity in EU5
13.6.1.1.3.4. Projected Opportunity in Rest of Europe
13.6.1.1.3.5. Projected Opportunity in Australia
13.6.1.1.3.6. Projected Opportunity in New Zealand
13.7. Encapsulated Cell Therapies for Neurological Disorders: Distribution by Indication
13.7.1. Encapsulated Cell Therapies Market for Neurological Disorders: Ataxia Telangiectasia, till 2030
13.7.1.1. EryDex System (EryDel)
13.7.1.1.1. Target Patient Population
13.7.1.1.2. Sales Forecast
13.7.1.1.3. Geographical Distribution of Projected Opportunity
13.7.1.1.3.1. Projected Opportunity in EU5
13.7.1.1.3.2. Projected Opportunity in Rest of Europe
13.7.1.1.3.3. Projected Opportunity in the US
13.7.1.1.3.4. Projected Opportunity in Australia
13.7.1.1.3.5. Projected Opportunity in India
13.7.1.1.3.6. Projected Opportunity in Israel
13.7.1.1.3.7. Projected Opportunity in Tunisia
13.7.2. Encapsulated Cell Therapies Market for Neurological Disorders: Parkinson’s Disease, until 2030
13.7.2.1. NTCELL® (Living Cell Technologies)
13.7.2.2. Target Patient Population
13.7.2.2.1. Sales Forecast
13.7.2.2.2. Geographical Distribution of Projected Opportunity
13.7.2.2.2.1. Projected Opportunity in New Zealand
13.7.2.2.2.2. Projected Opportunity in the US
13.7.2.2.2.3. Projected Opportunity in Australia
13.7.2.2.2.4. Projected Opportunity in EU5
13.7.2.2.2.5. Projected Opportunity in Rest of Europe
13.8. Encapsulated Cell Therapies for Oncological Disorders: Distribution by Indication
13.8.1. Encapsulated Cell Therapies Market for Oncological Disorders: Pancreatic Cancer, till 2030
13.8.1.1. GRASPA® (Erytech Pharma)
13.8.1.1.1. Target Patient Population
13.8.1.1.2. Sales Forecast
13.8.1.1.3. Geographical Distribution of Projected Opportunity
13.8.1.1.3.1. Projected Opportunity in EU5
13.8.1.1.3.2. Projected Opportunity in Rest of Europe
13.8.1.1.3.3. Projected Opportunity in the US
13.8.2. Encapsulated Cell Therapies Market for Oncological Disorders: Non-Metastatic Pancreatic Cancer, till 2030
13.8.2.1. Cell-in-a-Box® (PharmaCyte Biotech)
13.8.2.1.1. Target Patient Population
13.8.2.1.2. Sales Forecast
13.8.2.1.3. Geographical Distribution of Projected Opportunity
13.8.2.1.3.1. Projected Opportunity in the US
13.8.2.1.3.2. Projected Opportunity in EU5
13.8.2.1.3.3. Projected Opportunity of Cell-in-a-Box in Rest of Europe
13.8.3. Encapsulated Cell Therapies Market for Oncological Disorders: Triple Negative Breast Cancer, till 2030
13.8.3.1. GRASPA (Erytech Pharma)
13.8.3.1.1. Target Patient Population
13.8.3.1.2. Sales Forecast
13.8.3.1.3. Geographical Distribution of Projected Opportunity
13.8.3.1.3.1. Projected Opportunity in EU5
13.8.3.1.3.2. Projected Opportunity in Rest of Europe
13.8.3.1.3.3. Projected Opportunity in the US
13.8.4. Encapsulated Cell Therapies Market for Oncological Disorders: Head and Neck Cancer, till 2030
13.8.4.1. MVX-ONCO-1 (MaxiVAX)
13.8.4.1.1. Target Patient Population
13.8.4.1.2. Sales Forecast
13.8.4.1.3. Geographical Distribution of Projected Opportunity
13.8.4.1.3.1. Projected Opportunity in EU5
13.8.4.1.3.2. Projected Opportunity in Rest of Europe
13.8.4.1.3.3. Projected Opportunity in the US

14. CONCLUSION
14.1. Cell-based Pharmacological Interventions are Characterized by Diverse Challenges, Most of which can be Mitigated using Various Encapsulation Strategies
14.2. The Pipeline Features Several Mid and Late Stage Encapsulated Therapy Products, Majority of which are intended for the Treatment of Metabolic Disorders
14.3. The Fragmented Developer Landscape Includes a Mix of Small and Mid-Sized Players; at Present, North America and Europe are Major Hubs of Development Activity
14.4. The Heightened Pace of Research in this Domain is Evident from the Rise in the Number of Patents Filed / Granted and the Clinical Studies Conducted in the Recent Years
14.5. Development Efforts in this Field have Drawn Significant Capital Investments from Private and Public Investors; this is Likely to Provide the Necessary Impetus to the Market’s Future Growth
14.6. Growth in Partnership Activity Reflects the Rising Interest of Industry Stakeholders; Most Agreements are Between Technology Providers and Cell Therapy Developers
14.7. Given the Increasing Number of Licensing Deals and the Expected Approval of Multiple Mid-Late Stage Candidates, the Market is Poised to Grow at a Significant Pace in the Coming Years

15. EXECUTIVE INSIGHTS
15.1. Chapter Overview
15.2. Erytech Pharma
15.2.1. Company Snapshot
15.2.2. Interview Transcript: Alexander Scheer, Chief Scientific Officer
15.3. Defymed
15.3.1. Company Snapshot
15.3.2. Interview Transcript: Manuel Pires, Business Developer
15.4. Kadimastem
15.4.1. Company Snapshot
15.4.2. Interview Transcript: Michel Revel, Chief Scientist, and Galit Mazooz-Perlmuter, Business Development Manager
15.5. Aterelix
15.5.1. Company Snapshot
15.5.2. Interview Transcript: Mick Mclean, Chief Executive Officer
15.6. Neurotech Pharmaceuticals
15.6.1. Company Snapshot
15.6.2. Interview Transcript: Quinton Oswald, Former President and Chief Executive Officer
15.7. Seraxis
15.7.1. Company Snapshot
15.7.2. Interview Transcript: William L Rust, Founder and Chief Executive Officer
15.8. Beta-O2 Technologies
15.8.1. Company Snapshot
15.8.2. Interview Transcript: Yuval Avni, Former Chief Executive Officer

16. APPENDIX 1: TABULATED DATA

17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
 
List of Figures
Figure 3.1 Key Steps Involved in Manufacturing Cell Therapies
Figure 3.2 Cell Therapy Supply Chain
Figure 3.3 Encapsulation of Cells within Polymeric Membranes
Figure 3.4 Encapsulation of Active Drug Substances within Living Cells
Figure 3.5 Advantages of Encapsulated Cell Therapies and Encapsulation Technologies
Figure 3.6 Key Challenges Associated with Encapsulated Cell Therapies and Encapsulation Technologies
Figure 3.7 Potential Applications of Encapsulated Cell Therapies and Encapsulation Technologies
Figure 3.8 Growth Drivers and Road-blocks
Figure 4.1 Encapsulated Cell Therapies and Encapsulation Technologies: Distribution of Industry Players by Year of Establishment
Figure 4.2 Encapsulated Cell Therapies and Encapsulation Technologies: Distribution of Industry Players by Geographical Location
Figure 4.3 Encapsulated Cell Therapies and Encapsulation Technologies: Distribution of Industry Players by Company Size (Employee Count)
Figure 4.4 Encapsulated Cell Therapies and Encapsulation Technologies: Distribution of Industry Players by Type of Offering
Figure 4.5 Encapsulated Cell Therapies and Encapsulation Technologies: Distribution by Therapeutic Area
Figure 4.6 Encapsulated Cell Therapies and Encapsulation Technologies: Popular Disease Indications
Figure 4.7 Encapsulated Cell Therapies and Encapsulation Technologies: Distribution by Phase of Development
Figure 4.8 Encapsulated Cell Therapies and Encapsulation Technologies: Distribution by Therapeutic Area and Phase of Development
Figure 4.9 Encapsulated Cell Therapies and Encapsulation Technologies: Popular Type of Cells and Other Encapsulated Components
Figure 4.10 Encapsulated Cell Therapies and Encapsulation Technologies: Popular Type of Encapsulation Materials
Figure 4.11 Encapsulated Cell Therapies and Encapsulation Technologies: Grid Analysis
Figure 4.12 Encapsulated Cell Therapies and Encapsulation Technologies: Distribution by Route of Administration
Figure 4.13 Encapsulated Cell Therapies and Encapsulation Technologies: Distribution by Application Area
Figure 6.1 Living Cell Technologies: Revenues and Other Income, FY 2013 - FY 2018 (USD Million)
Figure 7.1 Patents Analysis: Distribution by Type
Figure 7.2 Patents Analysis: Cumulative Year-wise Trend, 2013-2018
Figure 7.3 Patents Analysis: Distribution by Geographical Location
Figure 7.4 Patents Analysis: Distribution by CPC Classifications (Top 20)
Figure 7.5 Patents Analysis: Emerging Focus Areas
Figure 7.6 Most Active Industry Players: Distribution by Number of Patents
Figure 7.7 Most Active Non-Industry Players: Distribution by Number of Patents
Figure 7.8 Patents Analysis: Benchmarking by Patent Characteristics
Figure 7.9 Patents Analysis: Benchmarking by Number of Patents Published Across Different Geographies
Figure 7.10 Patents Analysis: Benchmarking by Number of International Patents
Figure 7.11 Patents Analysis: Distribution by Patent Age, 2013-2018
Figure 7.12 Patents Analysis: Distribution by Geography and Publication Year, 2013-2018
Figure 7.13 Patents Analysis: Distribution by Relative Valuation
Figure 8.1. Clinical Trial Analysis: Distribution by Trial Status
Figure 8.2 Clinical Trial Analysis: Cumulative Distribution by Registration Year, Pre-2010-2018
Figure 8.3 Clinical Trial Analysis: Geographical Distribution of Trials
Figure 8.4 Clinical Trial Analysis: Geographical Distribution of Enrolled Patient Population
Figure 8.5 Clinical Trial Analysis: Distribution by Trial Phase
Figure 8.6 Clinical Trial Analysis: Distribution by Study Design
Figure 8.7 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 8.8 Most Active Industry Players: Distribution by Number of Registered Trials
Figure 8.9 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Figure 8.10 Clinical Trial Analysis: Popular Keywords
Figure 8.11 Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 8.12 Popular Indications: Distribution by Number of Registered Trials across Key Therapeutic Areas
Figure 8.13 Clinical Trial Analysis: Benchmarking by Number of Registered Trials
Figure 8.14 Clinical Trial Analysis: Distribution of Clinical Endpoints by Trial Phase
Figure 9.1 Recent Partnerships: Cumulative Year-wise Trend, 2013-2018
Figure 9.2 Recent Partnerships: Distribution by Type of Partnership
Figure 9.3 Recent Partnerships: Year-wise Trend by Type of Partnership
Figure 9.4 Recent Partnerships: Distribution by Therapeutic Area
Figure 9.5 Recent Partnerships: Popular Disease Indications
Figure 9.6 Recent Partnerships: Year-wise Trend by Therapeutic Area
Figure 9.7 Recent Partnerships: Popular Type of Cells and Other Encapsulated Components
Figure 9.8 Most Active Players: Distribution by Number of Partnerships
Figure 9.9 Most Active Players: Regional Distribution by Number of Partnerships
Figure 9.10 Recent Partnerships: Regional Distribution by Intercontinental and Intracontinental Agreements
Figure 10.1 Funding and Investments: Distribution of Companies by Year of Establishment and Type of Funding, 2013-2018
Figure 10.2 Funding and Investments: Distribution of Amount Invested by Focus Area and Type of Funding, 2013-2018
Figure 10.3 Funding and Investments: Cumulative Year-wise Trend, 2013-2018
Figure 10.4 Funding and Investments: Cumulative Amount Invested by Year, 2013-2018 (USD Million)
Figure 10.5 Funding and Investments: Distribution by Type of Funding
Figure 10.6 Funding and Investments: Distribution by Amount Invested and Type of Funding (USD Million)
Figure 10.7 Popular Indications: Distribution by Number of Funding Instances
Figure 10.8 Popular Indications: Distribution by Amount Invested (USD Million)
Figure 10.9 Funding Instances: Year-wise Trend of Amount Invested across Different Indications, 2013-2018 (USD Million)
Figure 10.10 Funding and Investments: Popular Type of Cells and Other Encapsulated Components by Amount Invested (USD Million)
Figure 10.11 Most Active Players: Distribution by Capital Amount Raised (USD Million)
Figure 10.12 Most Active Investors: Distribution by Number of Instances
Figure 10.13 Funding and Investments: Geographical Distribution by Amount Invested (USD Million)
Figure 10.14 Funding and Investment Summary
Figure 11.1 Academic Grant Analysis Cumulative Trend by Year of Award, 2013-2018
Figure 11.2 Academic Grant Analysis: Emerging Focus Areas
Figure 11.3 Academic Grant Analysis: Distribution by Support Period
Figure 11.4 Academic Grant Analysis: Distribution by Grant Type
Figure 11.5 Academic Grant Analysis: Year-wise Trend by Leading Grant Type
Figure 11.6 Academic Grant Analysis: Capital Amount Awarded by Grant Type
Figure 11.7 Academic Grant Analysis: Distribution by Responsible Study Section
Figure 11.8 Academic Grant Analysis: Distribution by Therapeutic Area
Figure 11.9 Popular Indications: Distribution by Number of Grants Awarded
Figure 11.10 Academic Grant Analysis: Year-wise Trend by Key Therapeutic Areas
Figure 11.11 Academic Grant Analysis: Benchmarking by Number of Grants Awarded across Key Therapeutic Areas
Figure 11.12 Academic Grant Analysis: Popular Types of Cells and Other Encapsulated Components
Figure 11.13 Academic Grant Analysis: Popular Types of Encapsulation Materials
Figure 11.14 Most Active Funding Institutes: Distribution by Number of Grants Awarded
Figure 11.15 Most Active Recipient Organizations: Distribution by Number of Grants Received
Figure 11.16 Academic Grant Analysis: Geographical Distribution of Recipient Organizations
Figure 13.1 Licensing Agreements: Distribution of Financial Components
Figure 13.2 Technology Licensing Deal: Payment Structure
Figure 13.3 Cell Encapsulation Technologies: Overall Market, 2019-2030 (USD Million)
Figure 13.4 Cell Encapsulation Technologies Market by Upfront Payments, 2019-2030 (USD Million)
Figure 13.5 Cell Encapsulation Technologies Market by Milestone Payments, 2019-2030 (USD Million)
Figure 13.6 Overall Encapsulated Cell Therapies Market, till 2030 (USD Million)
Figure 13.7 Encapsulated Cell Therapies Market for Eye Disorders, till 2030 (USD Million)
Figure 13.8 Encapsulated Cell Therapies Market for Metabolic Disorders, till 2030 (USD Million)
Figure 13.9 Encapsulated Cell Therapies Market for Neurological Disorders, till 2030 (USD Million)
Figure 13.10 Encapsulated Cell Therapies Market for Oncological Disorders, till 2030 (USD Million)
Figure 13.11 Encapsulated Cell Therapies Market for Alginate-based Microcapsules, till 2030 (USD Million)
Figure 13.12 Encapsulated Cell Therapies Market for Cellulose Hydrogels, till 2030 (USD Million)
Figure 13.13 Encapsulated Cell Therapies Market for Medical-grade Plastics, till 2030 (USD Million)
Figure 13.14 Encapsulated Cell Therapies Market for Red Blood Cells, till 2030 (USD Million)
Figure 13.15 Encapsulated Cell Therapies Market in North America, till 2030 (USD Million)
Figure 13.16 Encapsulated Cell Therapies Market in Europe, till 2030 (USD Million)
Figure 13.17 Encapsulated Cell Therapies Market in Asia-Pacific, till 2030 (USD Million)
Figure 13.18 Encapsulated Cell Therapies Market for Eye Disorders: Distribution by Indication, till 2030 (USD Million)
Figure 13.19 NT-501: Target Patient Population of Macular Telangiectasia
Figure 13.20 NT-501: Sales Forecast for Macular Telangiectasia, till 2030 (USD Million)
Figure 13.21 NT-501: Projected Opportunity for Macular Telangiectasia in the US, till 2030 (USD Million)
Figure 13.22 NT-501: Projected Opportunity for Macular Telangiectasia in EU5, till 2030 (USD Million)
Figure 13.23 NT-501: Projected Opportunity for Macular Telangiectasia in Rest of Europe, till 2030 (USD Million)
Figure 13.24 NT-501: Projected Opportunity for Macular Telangiectasia in Australia, till 2030 (USD Million)
Figure 13.25 NT-501: Target Patient Population of Glaucoma
Figure 13.26 NT-501: Sales Forecast for Glaucoma, till 2030 (USD Million)
Figure 13.27 NT-501: Projected Opportunity for Glaucoma in the US, till 2030 (USD Million)
Figure 13.28 NT-501: Projected Opportunity for Glaucoma in EU5, till 2030 (USD Million)
Figure 13.29 NT-501: Projected Opportunity for Glaucoma in Rest of Europe, till 2030 (USD Million)
Figure 13.30 NT-501: Projected Opportunity for Glaucoma in Australia, till 2030 (USD Million)
Figure 13.31 NT-501: Target Patient Population of Retinitis Pigmentosa
Figure 13.32 NT-501: Sales Forecast for Retinitis Pigmentosa, till 2030 (USD Million)
Figure 13.33 NT-501: Projected Opportunity for Retinitis Pigmentosa in the US, till 2030 (USD Million)
Figure 13.34 NT-501: Projected Opportunity for Retinitis Pigmentosa in EU5, till 2030 (USD Million)
Figure 13.35 NT-501: Projected Opportunity for Retinitis Pigmentosa in Rest of Europe, till 2030 (USD Million)
Figure 13.36 NT-501: Projected Opportunity for Retinitis Pigmentosa in Australia, till 2030 (USD Million)
Figure 13.37 Encapsulated Cell Therapies Market for Metabolic Disorders: Distribution by Indication, till 2030 (USD Million)
Figure 13.38 DIABECELL: Target Patient Population of Type 1 Diabetes
Figure 13.39 DIABECELL: Sales Forecast for Type 1 Diabetes, till 2030 (USD Million)
Figure 13.40 DIABECELL: Projected Opportunity for Type 1 Diabetes in the US, till 2030 (USD Million)
Figure 13.41 DIABECELL: Projected Opportunity for Type 1 Diabetes in Japan, till 2030 (USD Million)
Figure 13.42 DIABECELL: Projected Opportunity for Type 1 Diabetes in EU5, till 2030 (USD Million)
Figure 13.43 DIABECELL: Projected Opportunity for Type 1 Diabetes in Rest of Europe, till 2030 (USD Million)
Figure 13.44 DIABECELL: Projected Opportunity for Type 1 Diabetes in Australia, till 2030 (USD Million)
Figure 13.45 DIABECELL: Projected Opportunity for Type 1 Diabetes in New Zealand, till 2030 (USD Million)
Figure 13.46 Encapsulated Cell Therapies Market for Neurological Disorders: Distribution by Indication, till 2030 (USD Million)
Figure 13.47 EryDex System: Target Patient Population of Ataxia Telangiectasia
Figure 13.48 EryDex System: Sales Forecast for Ataxia Telangiectasia, till 2030 (USD Million)
Figure 13.49 EryDex System: Projected Opportunity for Ataxia Telangiectasia in EU5, till 2030 (USD Million)
Figure 13.50 EryDex System: Projected Opportunity for Ataxia Telangiectasia in Rest of Europe, till 2030 (USD Million)
Figure 13.51 EryDex System: Projected Opportunity for Ataxia Telangiectasia in the US, till 2030 (USD Million)
Figure 13.52 EryDex System: Projected Opportunity for Ataxia Telangiectasia in Australia, till 2030 (USD Million)
Figure 13.53 EryDex System: Projected Opportunity for Ataxia Telangiectasia in India, till 2030 (USD Million)
Figure 13.54 EryDex System: Projected Opportunity for Ataxia Telangiectasia in Israel, till 2030 (USD Million)
Figure 13.55 EryDex System: Projected Opportunity for Ataxia Telangiectasia in Tunisia, till 2030 (USD Million)
Figure 13.56 NTCELL: Target Patient Population of Parkinson’s Disease
Figure 13.57 NTCELL: Sales Forecast for Parkinson’s Disease, till 2030 (USD Million)
Figure 13.58 NTCELL: Projected Opportunity for Parkinson’s Disease in New Zealand, till 2030 (USD Million)
Figure 13.59 NTCELL: Projected Opportunity for Parkinson’s Disease in the US, till 2030 (USD Million)
Figure 13.60 NTCELL: Projected Opportunity for Parkinson’s Disease in Australia, till 2030 (USD Million)
Figure 13.61 NTCELL: Projected Opportunity for Parkinson’s Disease in EU5, till 2030 (USD Million)
Figure 13.62 NTCELL: Projected Opportunity for Parkinson’s Disease in Rest of Europe, till 2030 (USD Million)
Figure 13.63 Encapsulated Cell Therapies Market for Oncological Disorders: Distribution by Indication, till 2030 (USD Million)
Figure 13.64 GRASPA: Target Patient Population of Metastatic Pancreatic Cancer
Figure 13.65 GRASPA: Sales Forecast for Metastatic Pancreatic Cancer, till 2030 (USD Million)
Figure 13.66 GRASPA: Projected Opportunity for Metastatic Pancreatic Cancer in EU5, till 2030 (USD Million)
Figure 13.67 GRASPA: Projected Opportunity for Metastatic Pancreatic Cancer in Rest of Europe, till 2030 (USD Million)
Figure 13.68 GRASPA: Projected Opportunity for Metastatic Pancreatic Cancer in the US, till 2030 (USD Million)
Figure 13.69 Cell-in-a-Box: Target Patient Population of Non-Metastatic Pancreatic Cancer
Figure 13.70 Cell-in-a-Box: Sales Forecast for Non-Metastatic Pancreatic Cancer, till 2030 (USD Million)
Figure 13.71 Cell-in-a-Box: Projected Opportunity for Non-Metastatic Pancreatic Cancer in the US, till 2030 (USD Million)
Figure 13.72 Cell-in-a-Box: Projected Opportunity for Non-Metastatic Pancreatic Cancer in EU5, till 2030 (USD Million)
Figure 13.73 Cell-in-a-Box: Projected Opportunity for Non-Metastatic Pancreatic Cancer in rest of Europe, till 2030 (USD Million)
Figure 13.74 GRASPA: Target Patient Population of Triple Negative Breast Cancer
Figure 13.75 GRASPA: Sales Forecast for Triple Negative Breast Cancer, till 2030 (USD Million)
Figure 13.76 GRASPA: Projected Opportunity for Triple Negative Breast Cancer in EU5, till 2030 (USD Million)
Figure 13.77 GRASPA: Projected Opportunity for Triple Negative Breast Cancer in rest of Europe, till 2030 (USD Million)
Figure 13.78 GRASPA: Projected Opportunity for Triple Negative Breast Cancer in the US, till 2030 (USD Million)
Figure 13.79 MaxiVAX: Target Patient Population of Head and Neck Cancer
Figure 13.80 MVX-ONCO-1: Sales Forecast for Head and Neck Cancer, till 2030 (USD Million)
Figure 13.81 MVX-ONCO-1: Projected Opportunity for Head and Neck Cancer in EU5, till 2030 (USD Million)
Figure 13.82 MVX-ONCO-1: Projected Opportunity for Head and Neck Cancer in Rest of Europe, till 2030 (USD Million)
Figure 13.83 MVX-ONCO-1: Projected Opportunity for Head and Neck Cancer in the US, till 2030 (USD Million)

List of Tables
Table 3.1 Applications of Cell-based Therapies
Table 3.2 Types of Encapsulation Materials
Table 4.1 Encapsulated Cell Therapies and Encapsulation Technologies: Developer Overview
Table 4.2 Encapsulated Cell Therapies and Encapsulation Technologies: Development Pipeline
Table 4.3 Encapsulated Cell Therapies and Encapsulation Technologies: Distribution by Therapeutic Area and Phase of Development
Table 4.4 Encapsulated Cell Therapies and Encapsulation Technologies: Additional Information
Table 4.5 Encapsulated Cell Therapies and Encapsulation Technologies: Initiatives of Big Pharmaceutical Players
Table 5.1 Beta-O2 Technologies: Key Highlights
Table 5.2 Beta-O2 Technologies: Funding Instances
Table 5.3 Beta-O2 Technologies: Key Characteristics of βAir Bio-artificial Pancreas
Table 5.4 Beta-O2 Technologies: Recent Developments and Future Outlook
Table 5.5 Diatranz Otsuka: Key Highlights
Table 5.6 Diatranz Otsuka: Key Characteristics of DIABECELL®
Table 5.7 Diatranz Otsuka: Recent Developments and Future Outlook
Table 5.8 Sernova: Key Highlights
Table 5.9 Sernova: Funding Instances
Table 5.10 Sernova: Key Characteristics of Cell Pouch System™
Table 5.11 Sernova: Recent Developments and Future Outlook
Table 5.12 ViaCyte: Key Highlights
Table 5.13 ViaCyte: Funding Instances
Table 5.14 ViaCyte: Key Characteristics of PEC-Direct™ and PEC-Encap™
Table 5.15 ViaCyte: Recent Developments and Future Outlook
Table 5.16 Company 1: Key Highlights
Table 5.17 Company 2: Key Highlights
Table 5.18 Betalin Therapeutics: Key Highlights
Table 5.19 Company 4: Key Highlights
Table 5.20 Defymed: Key Highlights
Table 5.21 Company 6: Key Highlights
Table 5.22 Kadimastem: Key Highlights
Table 5.23 Company 8: Key Highlights
Table 5.24 Company 9: Key Highlights
Table 5.25 Company 10: Key Highlights
Table 5.26 Seraxis: Key Highlights
Table 5.27 Company 12: Key Highlights
Table 6.1 Azellon Cell Therapeutics: Key Highlights
Table 6.2 Azellon Cell Therapeutics: Key Characteristics of Cell Bandage
Table 6.3 Azellon Cell Therapeutics: Recent Developments and Future Outlook
Table 6.4 EryDel: Key Highlights
Table 6.5 EryDel: Funding Instances
Table 6.6 EryDel: Key Characteristics of EryDex System
Table 6.7 EryDel: Recent Developments and Future Outlook
Table 6.8 Erytech Pharma: Key Highlights
Table 6.9 Erytech Pharma: Funding Instances
Table 6.10 Erytech Pharma: Key Characteristics of GRASPA®
Table 6.11 Erytech Pharma: Recent Developments and Future Outlook
Table 6.12 Gloriana Therapeutics: Key Highlights
Table 6.13 Gloriana Therapeutics: Key Characteristics of EC-NGF
Table 6.14 Gloriana Therapeutics: Recent Developments and Future Outlook
Table 6.15 Living Cell Technologies: Key Highlights
Table 6.16 Living Cell Technologies: Key Characteristics of NTCELL®
Table 6.17 Living Cell Technologies: Recent Developments and Future Outlook
Table 6.18 MaxiVAX: Key Highlights
Table 6.19 MaxiVAX: Key Characteristics of MVX-ONCO-1
Table 6.20 MaxiVAX: Recent Developments and Future Outlook
Table 6.21 Neurotech Pharmaceuticals: Key Highlights
Table 6.22 Neurotech Pharmaceuticals: Key Characteristics of NT-501
Table 6.23 Neurotech Pharmaceuticals: Recent Developments and Future Outlook
Table 6.24 PharmaCyte Biotech: Key Highlights
Table 6.25 PharmaCyte Biotech: Funding Instances
Table 6.26 PharmaCyte Biotech: Key Characteristics of Cell-in-a-Box®
Table 6.27 PharmaCyte Biotech: Recent Developments and Future Outlook
Table 6.28 Company 1: Key Highlights
Table 6.29 Sernova: Key Highlights
Table 6.30 Company 3: Key Highlights
Table 7.1 Patents: CPC Classification Symbol Definitions
Table 7.2 Patents: Most Popular CPC Classification Symbols
Table 7.3 Patents: List of Top CPC Classifications
Table 7.4 Encapsulated Cell Therapies and Encapsulation Technologies: Summary of Patent Benchmarking Analysis
Table 7.5 Encapsulated Cell Therapies and Encapsulation Technologies: Categorizations based on Weighted Valuation Scores
Table 7.6 Leading Patents: Distribution by Relative Valuation
Table 7.7 Leading Patents: Distribution by Number of Citations
Table 8.1 Encapsulated Cell Therapies and Encapsulation Technologies: List of Clinical Trials
Table 8.2 Clinical Trials: Most Popular Clinical Endpoints by Phase of Development
Table 9.1 Encapsulated Cell Therapies and Encapsulation Technologies: List of Partnerships, 2013-2018
Table 9.2 Most Active Players: Distribution by Number of Partnerships
Table 10.1 Encapsulated Cell Therapies and Encapsulation Technologies: List of Funding Instances, 2013-2018
Table 10.2 Encapsulated Cell Therapies and Encapsulation Technologies: Summary of Investments
Table 11.1 Encapsulated Cell Therapies and Encapsulation Technologies: List of Academic Grants, 2013-2018
Table 11.2 Encapsulated Cell Therapies and Encapsulation Technologies: List of Academic Grants (Additional Information), 2013-2018
Table 12.1 Opportunities in North America: Most Likely Partners for Cell Therapy Development
Table 12.2 Opportunities in North America: Likely Partners for Cell Therapy Development
Table 12.3 Opportunities in North America: Less Likely Partners for Cell Therapy Development
Table 12.4 Opportunities in Europe: Most Likely Partners for Cell Therapy Development
Table 12.5 Opportunities in Europe: Likely Partners for Cell Therapy Development
Table 12.6 Opportunities in Europe: Less Likely Partners for Cell Therapy Development
Table 12.7 Opportunities in Asia-Pacific and Rest of the World: Most Likely Partners for Cell Therapy Development
Table 12.8 Opportunities in Asia-Pacific and Rest of the World: Likely Partners for Cell Therapy Development
Table 12.9 Opportunities in Asia-Pacific and Rest of the World: Less Likely Partners for Cell Therapy Development
Table 12.10 Opportunities in North America: Most Likely Partners for Cell Therapy Manufacturing
Table 12.11 Opportunities in North America: Likely Partners for Cell Therapy Manufacturing
Table 12.12 Opportunities in North America: Less Likely Partners for Cell Therapy Manufacturing
Table 12.13 Opportunities in Europe: Most Likely Partners for Cell Therapy Manufacturing
Table 12.14 Opportunities in Europe: Likely Partners for Cell Therapy Manufacturing
Table 12.15 Opportunities in Europe: Less Likely Partners for Cell Therapy Manufacturing
Table 12.16 Opportunities in Asia-Pacific and Rest of the World: Most Likely Partners for Cell Therapy Manufacturing
Table 12.17 Opportunities in Asia-Pacific and Rest of the World: Likely Partners for Cell Therapy Manufacturing
Table 12.18 Opportunities in Asia-Pacific and Rest of the World: Less Likely Partners for Cell Therapy Manufacturing
Table 13.1 Technology Licensing Deal: Tranches of Milestone Payments
Table 13.2 Cell Encapsulation Technologies: Average Upfront Payments and Average Milestone Payments, 2012-2018 (USD Million)
Table 13.3 List of Forecasted Encapsulated Cell Therapies
Table 13.4 Categorization of Likely Prices Considered for Encapsulated Cell Therapies
Table 13.5 Categorization of Expected Adoption Rates Considered for Encapsulated Cell Therapies
Table 15.1 Erytech Pharma: Key Highlights
Table 15.2 Defymed: Key Highlights
Table 15.3 Kadimastem: Key Highlights
Table 15.4 Aterelix: Key Highlights
Table 15.5 Neurotech Pharmaceuticals: Key Highlights
Table 15.6 Seraxis: Key Highlights
Table 15.7 Beta-O2 Technologies: Key Highlights
Table 16.1 Encapsulated Cell Therapies and Encapsulation Technologies: Distribution of Industry Players by Year of Establishment
Table 16.2 Encapsulated Cell Therapies and Encapsulation Technologies: Distribution of Industry Players by Geographical Location
Table 16.3 Encapsulated Cell Therapies and Encapsulation Technologies: Distribution of Industry Players by Company Size (Employee Count)
Table 16.4 Encapsulated Cell Therapies and Encapsulation Technologies: Distribution of Industry Players by Type of Offering
Table 16.5 Encapsulated Cell Therapies and Encapsulation Technologies: Distribution by Therapeutic Area
Table 16.6 Encapsulated Cell Therapies and Encapsulation Technologies: Popular Disease Indications
Table 16.7 Encapsulated Cell Therapies and Encapsulation Technologies: Distribution by Phase of Development
Table 16.8 Encapsulated Cell Therapies and Encapsulation Technologies: Distribution by Therapeutic Area and Phase of Development
Table 16.9 Encapsulated Cell Therapies and Encapsulation Technologies: Popular Type of Cells and Other Encapsulated Components
Table 16.10 Encapsulated Cell Therapies and Encapsulation Technologies: Popular Type of Encapsulation Materials
Table 16.11 Encapsulated Cell Therapies and Encapsulation Technologies: Distribution by Route of Administration
Table 16.12 Encapsulated Cell Therapies and Encapsulation Technologies: Distribution by Application Area
Table 16.13 Living Cell Technologies: Revenues and Other Income, FY 2013 - FY 2018 (USD Million)
Table 16.14 Patents Analysis: Distribution by Type
Table 16.15 Patents Analysis: Cumulative Year-wise Trend, 2013-2018
Table 16.16 Patents Analysis: Distribution by Geographical Location
Table 16.17 Patents Analysis: Distribution by CPC Classifications (Top 20)
Table 16.18 Most Active Industry Players: Distribution by Number of Patents
Table 16.19 Most Active Non-Industry Players: Distribution by Number of Patents
Table 16.20 Patents Analysis: Benchmarking by Patent Characteristics
Table 16.21 Patents Analysis: Benchmarking by Number of Patents Published Across Different Geographies
Table 16.22 Patents Analysis: Benchmarking by Number of International Patents
Table 16.23 Patents Analysis: Distribution by Patent Age, 2013-2018
Table 16.24 Patents Analysis: Distribution by Geography and Publication Year, 2013-2018
Table 16.25 Patents Analysis: Distribution by Relative Valuation
Table 16.26 Clinical Trial Analysis: Distribution by Trial Status
Table 16.27 Clinical Trial Analysis: Cumulative Distribution by Registration Year, Pre-2010-2018
Table 16.28 Clinical Trial Analysis: Geographical Distribution of Trials
Table 16.29 Clinical Trial Analysis: Geographical Distribution of Enrolled Patient Population
Table 16.30 Clinical Trial Analysis: Distribution by Trial Phase
Table 16.31 Clinical Trial Analysis: Distribution by Study Design
Table 16.32 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 16.33 Most Active Industry Players: Distribution by Number of Registered Trials
Table 16.34 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Table 16.35 Clinical Trial Analysis: Distribution by Therapeutic Area
Table 16.36 Popular Indications: Distribution by Number of Registered Trials across Key Therapeutic Areas
Table 16.37 Clinical Trial Analysis: Benchmarking by Number of Registered Trials
Table 16.38 Clinical Trial Analysis: Distribution of Clinical Endpoints by Trial Phase
Table 16.39 Recent Partnerships: Cumulative Year-wise Trend, 2013-2018
Table 16.40 Recent Partnerships: Distribution by Type of Partnership
Table 16.41 Recent Partnerships: Year-wise Trend by Type of Partnership
Table 16.42 Recent Partnerships: Distribution by Therapeutic Area
Table 16.43 Recent Partnerships: Popular Disease Indications
Table 16.44 Recent Partnerships: Year-wise Trend by Therapeutic Area
Table 16.45 Recent Partnerships: Popular Type of Cells and Other Encapsulated Components
Table 16.46 Most Active Players: Distribution by Number of Partnerships
Table 16.47 Most Active Players: Regional Distribution by Number of Partnerships
Table 16.48 Recent Partnerships: Regional Distribution by Intercontinental and Intracontinental Agreements
Table 16.49 Funding and Investments: Distribution of Companies by Year of Establishment and Type of Funding, 2013-2018
Table 16.50 Funding and Investments: Distribution of Amount Invested by Focus Area and Type of Funding, 2013-2018
Table 16.51 Funding and Investments: Cumulative Year-wise Trend, 2013-2018
Table 16.52 Funding and Investments: Cumulative Amount Invested by Year, 2013-2018 (USD Million)
Table 16.53 Funding and Investments: Distribution by Type of Funding
Table 16.54 Funding and Investments: Distribution by Amount Invested and Type of Funding (USD Million)
Table 16.55 Popular Indications: Distribution by Number of Funding Instances
Table 16.56 Popular Indications: Distribution by Amount Invested (USD Million)
Table 16.57 Funding Instances: Year-wise Trend of Amount Invested across Different Indications, 2013-2018 (USD Million)
Table 16.58 Funding and Investments: Popular Type of Cells and Other Encapsulated Components by Amount Invested (USD Million)
Table 16.59 Most Active Players: Distribution by Capital Amount Raised (USD Million)
Table 16.60 Most Active Investors: Distribution by Number of Instances
Table 16.61 Funding and Investments: Geographical Distribution by Amount Invested (USD Million)
Table 16.62 Academic Grant Analysis Cumulative Trend by Year of Award, 2013-2018
Table 16.63 Academic Grant Analysis: Distribution by Support Period
Table 16.64 Academic Grant Analysis: Distribution by Grant Type
Table 16.65 Academic Grant Analysis: Year-wise Trend by Leading Grant Type
Table 16.66 Academic Grant Analysis: Capital Amount Awarded by Grant Type
Table 16.67 Academic Grant Analysis: Distribution by Responsible Study Section
Table 16.68 Academic Grant Analysis: Distribution by Therapeutic Area
Table 16.69 Popular Indications: Distribution by Number of Grants Awarded
Table 16.70 Academic Grant Analysis: Year-wise Trend by Key Therapeutic Areas
Table 16.71 Academic Grant Analysis: Benchmarking by Number of Grants Awarded across Key Therapeutic Areas
Table 16.72 Academic Grant Analysis: Popular Types of Cells and Other Encapsulated Components
Table 16.73 Academic Grant Analysis: Popular Types of Encapsulation Materials
Table 16.74 Most Active Funding Institutes: Distribution by Number of Grants Awarded
Table 16.75 Most Active Recipient Organizations: Distribution by Number of Grants Received
Table 16.76 Academic Grant Analysis: Geographical Distribution of Recipient Organizations
Table 16.77 Overall Cell Encapsulation Technologies Market, Conservative Scenario, 2019-2030 (USD Million)
Table 16.78 Overall Cell Encapsulation Technologies Market, Base Scenario, 2019-2030 (USD Million)
Table 16.79 Overall Cell Encapsulation Technologies Market, Optimistic Scenario, 2019-2030 (USD Million)
Table 16.80 Cell Encapsulation Technologies Market by Upfront Payments, Conservative Scenario, till 2030 (USD Million)
Table 16.81 Cell Encapsulation Technologies Market by Upfront Payments, Base Scenario, till 2030 (USD Million)
Table 16.82 Cell Encapsulation Technologies Market by Upfront Payments, Optimistic Scenario, till 2030 (USD Million)
Table 16.83 Cell Encapsulation Technologies Market by Milestone Payments, Conservative Scenario, till 2030 (USD Million)
Table 16.84 Cell Encapsulation Technologies Market by Milestone Payments, Base Scenario, till 2030 (USD Million)
Table 16.85 Cell Encapsulation Technologies Market by Milestone Payments, Optimistic Scenario, till 2030 (USD Million)
Table 16.86 Overall Encapsulated Cell Therapies Market, Conservative Scenario, till 2030 (USD Million)
Table 16.87 Overall Encapsulated Cell Therapies Market, Base Scenario, till 2030 (USD Million)
Table 16.88 Overall Encapsulated Cell Therapies Market, Optimistic Scenario, till 2030 (USD Million)
Table 16.89 Encapsulated Cell Therapies Market for Eye Disorders, Conservative Scenario, till 2030 (USD Million)
Table 16.90 Encapsulated Cell Therapies Market for Eye Disorders, Base Scenario, till 2030 (USD Million)
Table 16.91 Encapsulated Cell Therapies Market for Eye Disorders, Optimistic Scenario, till 2030 (USD Million)
Table 16.92 Encapsulated Cell Therapies Market for Metabolic Disorders, Conservative Scenario, till 2030 (USD Million)
Table 16.93 Encapsulated Cell Therapies Market for Metabolic Disorders, Base Scenario, till 2030 (USD Million)
Table 16.94 Encapsulated Cell Therapies Market for Metabolic Disorders, Optimistic Scenario, till 2030 (USD Million)
Table 16.95 Encapsulated Cell Therapies Market for Neurological Disorders, Conservative Scenario, till 2030 (USD Million)
Table 16.96 Encapsulated Cell Therapies Market for Neurological Disorders, Base Scenario, till 2030 (USD Million)
Table 16.97 Encapsulated Cell Therapies Market for Neurological Disorders, Optimistic Scenario, till 2030 (USD Million)
Table 16.98 Encapsulated Cell Therapies Market for Oncological Disorders, Conservative Scenario, till 2030 (USD Million)
Table 16.99 Encapsulated Cell Therapies Market for Oncological Disorders, Base Scenario, till 2030 (USD Million)
Table 16.100 Encapsulated Cell Therapies Market for Oncological Disorders, Optimistic Scenario, till 2030 (USD Million)
Table 16.101 Encapsulated Cell Therapies Market for Alginate-based Microcapsules, Conservative Scenario, till 2030 (USD Million)
Table 16.102 Encapsulated Cell Therapies Market for Alginate-based Microcapsules, Base Scenario, till 2030 (USD Million)
Table 16.103 Encapsulated Cell Therapies Market for Alginate-based Microcapsules, Optimistic Scenario, till 2030 (USD Million)
Table 16.104 Encapsulated Cell Therapies Market for Cellulose Hydrogels, Conservative Scenario, till 2030 (USD Million)
Table 16.105 Encapsulated Cell Therapies Market for Cellulose Hydrogels, Base Scenario, till 2030 (USD Million)
Table 16.106 Encapsulated Cell Therapies Market for Cellulose Hydrogels, Optimistic Scenario, till 2030 (USD Million)
Table 16.107 Encapsulated Cell Therapies Market for Medical-grade Plastics, Conservative Scenario, till 2030 (USD Million)
Table 16.108 Encapsulated Cell Therapies Market for Medical-grade Plastics, Base Scenario, till 2030 (USD Million)
Table 16.109 Encapsulated Cell Therapies Market for Medical-grade Plastics, Optimistic Scenario, till 2030 (USD Million)
Table 16.110 Encapsulated Cell Therapies Market for Red Blood Cells, Conservative Scenario, till 2030 (USD Million)
Table 16.111 Encapsulated Cell Therapies Market for Red Blood Cells, Base Scenario, till 2030 (USD Million)
Table 16.112 Encapsulated Cell Therapies Market for Red Blood Cells, Optimistic Scenario, till 2030 (USD Million)
Table 16.113 Encapsulated Cell Therapies Market in North America, Conservative Scenario, till 2030 (USD Million)
Table 16.114 Encapsulated Cell Therapies Market in North America, Base Scenario, till 2030 (USD Million)
Table 16.115 Encapsulated Cell Therapies Market in North America, Optimistic Scenario, till 2030 (USD Million)
Table 16.116 Encapsulated Cell Therapies Market in Europe, Conservative Scenario, till 2030 (USD Million)
Table 16.117 Encapsulated Cell Therapies Market in Europe, Base Scenario, till 2030 (USD Million)
Table 16.118 Encapsulated Cell Therapies Market in Europe, Optimistic Scenario, till 2030 (USD Million)
Table 16.119 Encapsulated Cell Therapies Market in Asia-Pacific, Conservative Scenario, till 2030 (USD Million)
Table 16.120 Encapsulated Cell Therapies Market in Asia-Pacific, Base Scenario, till 2030 (USD Million)
Table 16.121 Encapsulated Cell Therapies Market in Asia-Pacific, Optimistic Scenario, till 2030 (USD Million)
Table 16.122 Encapsulated Cell Therapies Market for Eye Disorders: Distribution by Indication, Conservative Scenario, till 2030 (USD Million)
Table 16.123 Encapsulated Cell Therapies Market for Eye Disorders: Distribution by Indication, Base Scenario, till 2030 (USD Million)
Table 16.124 Encapsulated Cell Therapies Market for Eye Disorders: Distribution by Indication, Optimistic Scenario, till 2030 (USD Million)
Table 16.125 NT-501: Sales Forecast for Macular Telangiectasia, Conservative Scenario, till 2030 (USD Million)
Table 16.126 NT-501: Sales Forecast for Macular Telangiectasia, Base Scenario, till 2030 (USD Million)
Table 16.127 NT-501: Sales Forecast for Macular Telangiectasia, Optimistic Scenario, till 2030 (USD Million)
Table 16.128 NT-501: Projected Opportunity for Macular Telangiectasia in the US, Conservative Scenario, till 2030 (USD Million)
Table 16.129 NT-501: Projected Opportunity for Macular Telangiectasia in the US, Base Scenario, till 2030 (USD Million)
Table 16.130 NT-501: Projected Opportunity for Macular Telangiectasia in the US, Optimistic Scenario, till 2030 (USD Million)
Table 16.131 NT-501: Projected Opportunity for Macular Telangiectasia in EU5, Conservative Scenario, till 2030 (USD Million)
Table 16.132 NT-501: Projected Opportunity for Macular Telangiectasia in EU5, Base Scenario, till 2030 (USD Million)
Table 16.133 NT-501: Projected Opportunity for Macular Telangiectasia in EU5, Optimistic Scenario, till 2030 (USD Million)
Table 16.134 NT-501: Projected Opportunity for Macular Telangiectasia in Rest of Europe, Conservative Scenario, till 2030 (USD Million)
Table 16.135 NT-501: Projected Opportunity for Macular Telangiectasia in Rest of Europe, Base Scenario, till 2030 (USD Million)
Table 16.136 NT-501: Projected Opportunity for Macular Telangiectasia in Rest of Europe, Optimistic Scenario, till 2030 (USD Million)
Table 16.137 NT-501: Projected Opportunity for Macular Telangiectasia in Australia, Conservative Scenario, till 2030 (USD Million)
Table 16.138 NT-501: Projected Opportunity for Macular Telangiectasia in Australia, Base Scenario, till 2030 (USD Million)
Table 16.139 NT-501: Projected Opportunity for Macular Telangiectasia in Australia, Optimistic Scenario, till 2030 (USD Million)
Table 16.140 NT-501: Sales Forecast for Glaucoma, Conservative Scenario, till 2030 (USD Million)
Table 16.141 NT-501: Sales Forecast for Glaucoma, Base Scenario, till 2030 (USD Million)
Table 16.142 NT-501: Sales Forecast for Glaucoma, Optimistic Scenario, till 2030 (USD Million)
Table 16.143 NT-501: Projected Opportunity for Glaucoma in the US, Conservative Scenario, till 2030 (USD Million)
Table 16.144 NT-501: Projected Opportunity for Glaucoma in the US, Base Scenario, till 2030 (USD Million)
Table 16.145 NT-501: Projected Opportunity for Glaucoma in the US, Optimistic Scenario, till 2030 (USD Million)
Table 16.146 NT-501: Projected Opportunity for Glaucoma in EU5, Conservative Scenario, till 2030 (USD Million)
Table 16.147 NT-501: Projected Opportunity for Glaucoma in EU5, Base Scenario, till 2030 (USD Million)
Table 16.148 NT-501: Projected Opportunity for Glaucoma in EU5, Optimistic Scenario, till 2030 (USD Million)
Table 16.149 NT-501: Projected Opportunity for Glaucoma in Rest of Europe, Conservative Scenario, till 2030 (USD Million)
Table 16.150 NT-501: Projected Opportunity for Glaucoma in Rest of Europe, Base Scenario, till 2030 (USD Million)
Table 16.151 NT-501: Projected Opportunity for Glaucoma in Rest of Europe, Optimistic Scenario, till 2030 (USD Million)
Table 16.152 NT-501: Projected Opportunity for Glaucoma in Australia, Conservative Scenario, till 2030 (USD Million)
Table 16.153 NT-501: Projected Opportunity for Glaucoma in Australia, Base Scenario, till 2030 (USD Million)
Table 16.154 NT-501: Projected Opportunity for Glaucoma in Australia, Optimistic Scenario, till 2030 (USD Million)
Table 16.155 NT-501: Sales Forecast for Retinitis Pigmentosa, Conservative Scenario, till 2030 (USD Million)
Table 16.156 NT-501: Sales Forecast for Retinitis Pigmentosa, Base Scenario, till 2030 (USD Million)
Table 16.157 NT-501: Sales Forecast for Retinitis Pigmentosa, Optimistic Scenario, till 2030 (USD Million)
Table 16.158 NT-501: Projected Opportunity for Retinitis Pigmentosa in the US, Conservative Scenario, till 2030 (USD Million)
Table 16.159 NT-501: Projected Opportunity for Retinitis Pigmentosa in the US, Base Scenario, till 2030 (USD Million)
Table 16.160 NT-501: Projected Opportunity for Retinitis Pigmentosa in the US, Optimistic Scenario, till 2030 (USD Million)
Table 16.161 NT-501: Projected Opportunity for Retinitis Pigmentosa in EU5, Conservative Scenario, till 2030 (USD Million)
Table 16.162 NT-501: Projected Opportunity for Retinitis Pigmentosa in EU5, Base Scenario, till 2030 (USD Million)
Table 16.163 NT-501: Projected Opportunity for Retinitis Pigmentosa in EU5, Optimistic Scenario, till 2030 (USD Million)
Table 16.164 NT-501: Projected Opportunity for Retinitis Pigmentosa in Rest of Europe, Conservative Scenario, till 2030 (USD Million)
Table 16.165 NT-501: Projected Opportunity for Retinitis Pigmentosa in Rest of Europe, Base Scenario, till 2030 (USD Million)
Table 16.166 NT-501: Projected Opportunity for Retinitis Pigmentosa in Rest of Europe, Optimistic Scenario, till 2030 (USD Million)
Table 16.167 NT-501: Projected Opportunity for Retinitis Pigmentosa in Australia, Conservative Scenario, till 2030 (USD Million)
Table 16.168 NT-501: Projected Opportunity for Retinitis Pigmentosa in Australia, Base Scenario, till 2030 (USD Million)
Table 16.169 NT-501: Projected Opportunity for Retinitis Pigmentosa in Australia, Optimistic Scenario, till 2030 (USD Million)
Table 16.170 Encapsulated Cell Therapies Market for Metabolic Disorders: Distribution by Indication, Conservative Scenario, till 2030(USD Million)
Table 16.171 Encapsulated Cell Therapies Market for Metabolic Disorders: Distribution by Indication, Base Scenario, till 2030 (USD Million)
Table 16.172 Encapsulated Cell Therapies Market for Metabolic Disorders: Distribution by Indication, Optimistic Scenario, till 2030 (USD Million)
Table 16.173 DIABECELL®®: Sales Forecast for Type 1 diabetes, Conservative Scenario, till 2030 (USD Million)
Table 16.174 DIABECELL®®: Sales Forecast for Type 1 diabetes, Base Scenario, till 2030 (USD Million)
Table 16.175 DIABECELL®®: Sales Forecast for Type 1 diabetes, Optimistic Scenario, till 2030 (USD Million)
Table 16.176 DIABECELL®: Projected Opportunity for Type 1 Diabetes in the US, Conservative Scenario, till 2030 (USD Million)
Table 16.177 DIABECELL®: Projected Opportunity for Type 1 Diabetes in the US, Base Scenario, till 2030 (USD Million)
Table 16.178 DIABECELL®: Projected Opportunity for Type 1 Diabetes in the US, Optimistic Scenario, till 2030 (USD Million)
Table 16.179 DIABECELL®: Projected Opportunity for Type 1 Diabetes in Japan, Conservative Scenario, till 2030 (USD Million)
Table 16.180 DIABECELL®: Projected Opportunity for Type 1 Diabetes in Japan, Base Scenario, till 2030 (USD Million)
Table 16.181 DIABECELL®: Projected Opportunity for Type 1 Diabetes in Japan, Optimistic Scenario, till 2030 (USD Million)
Table 16.182 DIABECELL®: Projected Opportunity for Type 1 Diabetes in EU5, Conservative Scenario, till 2030 (USD Million)
Table 16.183 DIABECELL®: Projected Opportunity for Type 1 Diabetes in EU5, Base Scenario, till 2030 (USD Million)
Table 16.184 DIABECELL®: Projected Opportunity for Type 1 Diabetes in EU5, Optimistic Scenario, till 2030 (USD Million)
Table 16.185 DIABECELL®: Projected Opportunity for Type 1 Diabetes in Rest of Europe, Conservative Scenario, till 2030 (USD Million)
Table 16.186 DIABECELL®: Projected Opportunity for Type 1 Diabetes in Rest of Europe, Base Scenario, till 2030 (USD Million)
Table 16.187 DIABECELL®: Projected Opportunity for Type 1 Diabetes in Rest of Europe, Optimistic Scenario, till 2030 (USD Million)
Table 16.188 DIABECELL®: Projected Opportunity for Type 1 Diabetes in Australia, Conservative Scenario, till 2030 (USD Million)
Table 16.189 DIABECELL®: Projected Opportunity for Type 1 Diabetes in Australia, Base Scenario, till 2030 (USD Million)
Table 16.190 DIABECELL®: Projected Opportunity for Type 1 Diabetes in Australia, Optimistic Scenario, till 2030 (USD Million)
Table 16.191 DIABECELL®: Projected Opportunity for Type 1 Diabetes in New Zealand, Conservative Scenario, till 2030 (USD Million)
Table 16.192 DIABECELL®: Projected Opportunity for Type 1 Diabetes in New Zealand, Base Scenario, till 2030 (USD Million)
Table 16.193 DIABECELL®: Projected Opportunity for Type 1 Diabetes in New Zealand, Optimistic Scenario, till 2030 (USD Million)
Table 16.194 Encapsulated Cell Therapies Market for Neurological Disorders: Distribution by Indication, Conservative Scenario, till 2030 (USD Million)
Table 16.195 Encapsulated Cell Therapies Market for Neurological Disorders: Distribution by Indication, Base Scenario, till 2030 (USD Million)
Table 16.196 Encapsulated Cell Therapies Market for Neurological Disorders: Distribution by Indication, Optimistic Scenario, till 2030 (USD Million)
Table 16.197 EryDex System: Sales Forecast for Ataxia Telangiectasia, Conservative Scenario, till 2030 (USD Million)
Table 16.198 EryDex System: Sales Forecast for Ataxia Telangiectasia, Base Scenario, till 2030 (USD Million)
Table 16.199 EryDex System: Sales Forecast for Ataxia Telangiectasia, Optimistic Scenario, till 2030 (USD Million)
Table 16.200 EryDex System: Projected Opportunity for Ataxia Telangiectasia in EU5, Conservative Scenario, till 2030 (USD Million)
Table 16.201 EryDex System: Projected Opportunity for Ataxia Telangiectasia in EU5, Base Scenario, till 2030 (USD Million)
Table 16.202 EryDex System: Projected Opportunity for Ataxia Telangiectasia in EU5, Optimistic Scenario, till 2030 (USD Million)
Table 16.203 EryDex System: Projected Opportunity for Ataxia Telangiectasia in Rest of Europe, Conservative Scenario, till 2030 (USD Million)
Table 16.204 EryDex System: Projected Opportunity for Ataxia Telangiectasia in Rest of Europe, Base Scenario, till 2030 (USD Million)
Table 16.205 EryDex System: Projected Opportunity for Ataxia Telangiectasia in Rest of Europe, Optimistic Scenario, till 2030 (USD Million)
Table 16.206 EryDex System: Projected Opportunity for Ataxia Telangiectasia in the US, Conservative Scenario, till 2030 (USD Million)
Table 16.207 EryDex System: Projected Opportunity for Ataxia Telangiectasia in the US, Base Scenario, till 2030 (USD Million)
Table 16.208 EryDex System: Projected Opportunity for Ataxia Telangiectasia in the US, Optimistic Scenario, till 2030 (USD Million)
Table 16.209 EryDex System: Projected Opportunity for Ataxia Telangiectasia in Australia, Conservative Scenario, till 2030 (USD Million)
Table 16.210 EryDex System: Projected Opportunity for Ataxia Telangiectasia in Australia, Base Scenario, till 2030 (USD Million)
Table 16.211 EryDex System: Projected Opportunity for Ataxia Telangiectasia in Australia, Optimistic Scenario, till 2030 (USD Million)
Table 16.212 EryDex System: Projected Opportunity for Ataxia Telangiectasia in India, Conservative Scenario, till 2030 (USD Million)
Table 16.213 EryDex System: Projected Opportunity for Ataxia Telangiectasia in India, Base Scenario, till 2030 (USD Million)
Table 16.214 EryDex System: Projected Opportunity for Ataxia Telangiectasia in India, Optimistic Scenario, till 2030 (USD Million)
Table 16.215 EryDex System: Projected Opportunity for Ataxia Telangiectasia in Israel, Conservative Scenario, till 2030 (USD Million)
Table 16.216 EryDex System: Projected Opportunity for Ataxia Telangiectasia in Israel, Base Scenario, till 2030 (USD Million)
Table 16.217 EryDex System: Projected Opportunity for Ataxia Telangiectasia in Israel, Optimistic Scenario, till 2030 (USD Million)
Table 16.218 EryDex System: Projected Opportunity for Ataxia Telangiectasia in Tunisia, Conservative Scenario, till 2030 (USD Million)
Table 16.219 EryDex System: Projected Opportunity for Ataxia Telangiectasia in Tunisia, Base Scenario, till 2030 (USD Million)
Table 16.220 EryDex System: Projected Opportunity for Ataxia Telangiectasia in Tunisia, Optimistic Scenario, till 2030 (USD Million)
Table 16.221 NTCELL®®: Sales Forecast for Parkinson’s Disease, Conservative Scenario, till 2030 (USD Million)
Table 16.222 NTCELL®: Sales Forecast for Parkinson’s Disease, Base Scenario, till 2030 (USD Million)
Table 16.223 NTCELL®: Sales Forecast for Parkinson’s Disease, Optimistic Scenario, till 2030 (USD Million)
Table 16.224 NTCELL®: Projected Opportunity for Parkinson’s Disease in New Zealand, Conservative Scenario, till 2030 (USD Million)
Table 16.225 NTCELL®: Projected Opportunity for Parkinson’s Disease in New Zealand, Base Scenario, till 2030 (USD Million)
Table 16.226 NTCELL®: Projected Opportunity for Parkinson’s Disease in New Zealand, Optimistic Scenario, till 2030 (USD Million)
Table 16.227 NTCELL®: Projected Opportunity for Parkinson’s Disease in the US, Conservative Scenario, till 2030 (USD Million)
Table 16.228 NTCELL®: Projected Opportunity for Parkinson’s Disease in the US, Base Scenario, till 2030 (USD Million)
Table 16.229 NTCELL®: Projected Opportunity for Parkinson’s Disease in the US, Optimistic Scenario, till 2030 (USD Million)
Table 16.230 NTCELL®: Projected Opportunity for Parkinson’s Disease in Australia, Conservative Scenario, till 2030 (USD Million)
Table 16.231 NTCELL®: Projected Opportunity for Parkinson’s Disease in Australia, Base Scenario, till 2030 (USD Million)
Table 16.232 NTCELL®: Projected Opportunity for Parkinson’s Disease in Australia, Optimistic Scenario, till 2030 (USD Million)
Table 16.233 NTCELL®: Projected Opportunity for Parkinson’s Disease in EU5, Conservative Scenario, till 2030 (USD Million)
Table 16.234 NTCELL®: Projected Opportunity for Parkinson’s Disease in EU5, Base Scenario, till 2030 (USD Million)
Table 16.235 NTCELL®: Projected Opportunity for Parkinson’s Disease in EU5, Optimistic Scenario, till 2030 (USD Million)
Table 16.236 NTCELL®: Projected Opportunity for Parkinson’s Disease in Rest of Europe, Conservative Scenario, till 2030 (USD Million)
Table 16.237 NTCELL®: Projected Opportunity for Parkinson’s Disease in Rest of Europe, Base Scenario, till 2030 (USD Million)
Table 16.238 NTCELL®: Projected Opportunity for Parkinson’s Disease in Rest of Europe, Optimistic Scenario, till 2030 (USD Million)
Table 16.239 Encapsulated Cell Therapies Market for Oncological Disorders: Distribution by Indication, Conservative Scenario, till 2030 (USD Million)
Table 16.240 Encapsulated Cell Therapies Market for Oncological Disorders: Distribution by Indication, Base Scenario, till 2030 (USD Million)
Table 16.241 Encapsulated Cell Therapies Market for Oncological Disorders: Distribution by Indication, Optimistic Scenario, till 2030(USD Million)
Table 16.242 GRASPA®®: Sales Forecast for Metastatic Pancreatic Cancer, Conservative Scenario, till 2030 (USD Million)
Table 16.243 GRASPA®: Sales Forecast for Metastatic Pancreatic Cancer, Base Scenario, till 2030 (USD Million)
Table 16.244 GRASPA®: Sales Forecast for Metastatic Pancreatic Cancer, Optimistic Scenario, till 2030 (USD Million)
Table 16.245 GRASPA®: Projected Opportunity for Metastatic Pancreatic Cancer in EU5, Conservative Scenario, till 2030 (USD Million)
Table 16.246 GRASPA®: Projected Opportunity for Metastatic Pancreatic Cancer in EU5, Base Scenario, till 2030 (USD Million)
Table 16.247 GRASPA®: Projected Opportunity for Metastatic Pancreatic Cancer in EU5, Optimistic Scenario, till 2030 (USD Million)
Table 16.248 GRASPA®: Projected Opportunity for Metastatic Pancreatic Cancer in Rest of Europe, Conservative Scenario, till 2030 (USD Million)
Table 16.249 GRASPA®: Projected Opportunity for Metastatic Pancreatic Cancer in Rest of Europe, Base Scenario, till 2030 (USD Million)
Table 16.250 GRASPA®: Projected Opportunity for Metastatic Pancreatic Cancer in Rest of Europe, Optimistic Scenario, till 2030 (USD Million)
Table 16.251 GRASPA®: Projected Opportunity for Metastatic Pancreatic Cancer in the US, Conservative Scenario, till 2030 (USD Million)
Table 16.252 GRASPA®: Projected Opportunity for Metastatic Pancreatic Cancer in the US, Base Scenario, till 2030 (USD Million)
Table 16.253 GRASPA®: Projected Opportunity for Metastatic Pancreatic Cancer in the US, Optimistic Scenario, till 2030 (USD Million)
Table 16.254 Cell-in-a-Box®®: Sales Forecast for Non-Metastatic Pancreatic Cancer, Conservative Scenario, till 2030 (USD Million)
Table 16.255 Cell-in-a-Box®: Sales Forecast for Non-Metastatic Pancreatic Cancer, Base Scenario, till 2030 (USD Million)
Table 16.256 Cell-in-a-Box®: Sales Forecast for Non-Metastatic Pancreatic Cancer, Optimistic Scenario, till 2030 (USD Million)
Table 16.257 Cell-in-a-Box®: Projected Opportunity for Non-Metastatic Pancreatic Cancer in the US, Conservative Scenario, till 2030 (USD Million)
Table 16.258 Cell-in-a-Box®: Projected Opportunity for Non-Metastatic Pancreatic Cancer in the US, Base Scenario, till 2030 (USD Million)
Table 16.259 Cell-in-a-Box®: Projected Opportunity for Non-Metastatic Pancreatic Cancer in the US, Optimistic Scenario, till 2030 (USD Million)
Table 16.260 Cell-in-a-Box®: Projected Opportunity for Non-Metastatic Pancreatic Cancer in EU5, Conservative Scenario, till 2030 (USD Million)
Table 16.261 Cell-in-a-Box®: Projected Opportunity for Non-Metastatic Pancreatic Cancer in EU5, Base Scenario, till 2030 (USD Million)
Table 16.262 Cell-in-a-Box®: Projected Opportunity for Non-Metastatic Pancreatic Cancer in EU5, Optimistic Scenario, till 2030 (USD Million)
Table 16.263 Cell-in-a-Box®: Projected Opportunity for Non-Metastatic Pancreatic Cancer in Rest of Europe, Conservative Scenario, till2030 (USD Million)
Table 16.264 Cell-in-a-Box®: Projected Opportunity for Non-Metastatic Pancreatic Cancer in Rest of Europe, Base Scenario, till 2030 (USD Million)
Table 16.265 Cell-in-a-Box®: Projected Opportunity for Non-Metastatic Pancreatic Cancer in Rest of Europe, Optimistic Scenario, till 2030 (USD Million)
Table 16.266 GRASPA®: Sales Forecast for Triple Negative Breast Cancer, Conservative Scenario, till 2030 (USD Million)
Table 16.267 GRASPA®: Sales Forecast for Triple Negative Breast Cancer, Base Scenario, till 2030 (USD Million)
Table 16.268 GRASPA®: Sales Forecast for Metastatic Pancreatic Cancer, Optimistic Scenario, till 2030 (USD Million)
Table 16.269 GRASPA®: Projected Opportunity for Triple Negative Breast Cancer in EU5, Conservative Scenario, till 2030 (USD Million)
Table 16.270 GRASPA®: Projected Opportunity for Triple Negative Breast Cancer in EU5, Base Scenario, till 2030 (USD Million)
Table 16.271 GRASPA®: Projected Opportunity for Triple Negative Breast Cancer in EU5, Optimistic Scenario, till 2030 (USD Million)
Table 16.272 GRASPA®: Projected Opportunity for Triple Negative Breast Cancer in Rest of Europe, Conservative Scenario, till 2030 (USD Million)
Table 16.273 GRASPA®: Projected Opportunity for Triple Negative Breast Cancer in Rest of Europe, Base Scenario, till 2030 (USD Million)
Table 16.274 GRASPA®: Projected Opportunity for Triple Negative Breast Cancer in Rest of Europe, Optimistic Scenario, till 2030 (USD Million)
Table 16.275 GRASPA®: Projected Opportunity for Triple Negative Breast Cancer in the US, Conservative Scenario, till 2030 (USD Million)
Table 16.276 GRASPA®: Projected Opportunity for Triple Negative Breast Cancer in the US, Base Scenario, till 2030 (USD Million)
Table 16.277 GRASPA®: Projected Opportunity for Triple Negative Breast Cancer in the US, Optimistic Scenario, till 2030 (USD Million)
Table 16.278 MVX-ONCO-1: Sales Forecast for Head and Neck Cancer, Conservative Scenario, till 2030 (USD Million)
Table 16.279 MVX-ONCO-1: Sales Forecast for Head and Neck Cancer, Base Scenario, till 2030 (USD Million)
Table 16.280 MVX-ONCO-1: Sales Forecast for Head and Neck Cancer, Optimistic Scenario, till 2030 (USD Million)
Table 16.281 MVX-ONCO-1: Projected Opportunity for Head and Neck Cancer in EU5, Conservative Scenario, till 2030 (USD Million)
Table 16.282 MVX-ONCO-1: Projected Opportunity for Head and Neck Cancer in EU5, Base Scenario, till 2030 (USD Million)
Table 16.283 MVX-ONCO-1: Projected Opportunity for Head and Neck Cancer in EU5, Optimistic Scenario, till 2030 (USD Million)
Table 16.284 MVX-ONCO-1: Projected Opportunity for Head and Neck Cancer in Rest of Europe, Conservative Scenario, till 2030 (USD Million)
Table 16.285 MVX-ONCO-1: Projected Opportunity for Head and Neck Cancer in Rest of Europe, Base Scenario, till 2030 (USD Million)
Table 16.286 MVX-ONCO-1: Projected Opportunity for Head and Neck Cancer in Rest of Europe, Optimistic Scenario, till 2030 (USD Million)
Table 16.287 MVX-ONCO-1: Projected Opportunity for Head and Neck Cancer in the US, Conservative Scenario, till 2030 (USD Million)
Table 16.288 MVX-ONCO-1: Projected Opportunity for Head and Neck Cancer in the US, Base Scenario, till 2030 (USD Million)
Table 16.289 MVX-ONCO-1: Projected Opportunity for Head and Neck Cancer in the US, Optimistic Scenario, till 2030 (USD Million)

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • 24Haymarket
  • Caladrius Biosciences
  • Eutilex
  • Kadimastem
  • OhioHealth
  • StemBios Technologies
  • MORE

Chapter Outlines

  • Chapter 2 is an executive summary of the insights captured in our research. The summary offers a high-level view of the likely evolution of encapsulated cell therapies and affiliated technologies market in the mid to long term.
  • Chapter 3 is an introductory chapter that presents a general overview of cell-based therapies and the intricacies of their development and administration, along with information on the key challenges associated with them. Further, it features a detailed discussion on cell encapsulation, including a comprehensive history of development, and information on different types of cell encapsulation methods and materials. It also features a discussion on the key advantages/challenges associated with encapsulated cell therapies and affiliated technologies, providing information on their potential usability across different application areas. Further, the chapter features a discussion on the key growth drivers and roadblocks related to cell encapsulation technologies and their use in treating various chronic conditions.
  • Chapter 4 includes information on more than 40 encapsulated cell therapies and affiliated technologies that are currently being developed by industry players for treating different chronic conditions. It features a comprehensive analysis of pipeline therapies and technologies, highlighting the target disease indications, phase of development, encapsulation method, type of cells / API, and route of administration. The chapter also highlights the contributions of various stakeholder companies that are developing novel encapsulation methods/techniques for use in storage and transportation of cells, as well as other applications. Additionally, the chapter features information on the initiatives undertaken by big pharmaceutical companies and academic players within this domain.
  • Chapter 5 includes elaborate profiles of industry players that are currently engaged in the clinical development of their proprietary encapsulated cell therapies for the treatment of metabolic disorders; each profile features an overview of the company, its financial information (if available), and a detailed description of its product(s), highlighting mechanism of action, current development status, and key clinical trial results. Each profile also includes a list of recent developments, the key milestones achieved, partnership activity, and the likely strategies that may be adopted by these players to fuel growth in the foreseen future. Further, for developers with early stage (preclinical) candidates, we have presented brief profiles, highlighting key details about the company, product portfolio, recent developments, and the likely roadmap / future plans related to the development and commercialization of their products (if available).
  • Chapter 6 includes elaborate profiles of industry players that are currently engaged in the clinical development of their proprietary encapsulated cell therapies for the treatment of non-metabolic disorders; each profile features an overview of the company, its financial information (if available), and a detailed description of its product (s), highlighting mechanism of action, current development status, and key clinical trial results. Each profile also includes a list of recent developments, the key milestones achieved, partnership activity, and the likely strategies that may be adopted by these players to fuel growth in the foreseen future. Further, for developers with early stage (preclinical) candidates, we have presented brief profiles, highlighting key details about the company, product portfolio, recent developments, and the likely roadmap / future plans related to the development and commercialization of their products (if available).
  • Chapter 7 provides an in-depth patent analysis to provide an overview of how the industry is evolving from the R&D perspective. For this analysis, we considered those patents that have been published since 2013 related to the cell encapsulation domain. The analysis also highlights the key trends associated with these patents, including patent type, regional applicability, CPC classification, emerging focus areas, leading industry players (in terms of the number of patents filed/granted), and current intellectual property-related benchmarks and valuation.
  • Chapter 8 provides a comprehensive clinical trial analysis of completed, ongoing and planned studies of various encapsulated cell therapies. The analysis highlights the key trends associated with these clinical studies across various parameters, such as trial start year, trial status, phase of development, leading industry and non-industry players (in terms of number of trials conducted), study design, targeted therapeutic area, key indications, study focus, clinical endpoints, and enrolled patient population and regional distribution of trials.
  • Chapter 9 features an elaborate discussion and analysis of partnerships/collaborations that have been established in the domain in the period 2013-2018. It includes a brief description of various types of partnership models (such as product development/commercialization agreements, R&D collaborations, technology licensing deals, distribution agreements, mergers/acquisitions, and others) that have been employed by stakeholders within this domain. It also consists of a schematic representation showcasing the players that have established the maximum number of alliances related to encapsulated cell therapies and affiliated technologies. Furthermore, we have provided a world map representation of all the deals inked in this field, highlighting those that have been established within and across different continents.
  • Chapter 10 provides information on funding instances and investments that have been made within the cell encapsulation domain. The chapter includes details on various types of investments (such as seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings) received by companies between 2013 and 2018, highlighting the growing interest of the venture capital community and other strategic investors in this domain.
  • Chapter 11 provides a detailed analysis of academic grants that have been awarded to support research related to encapsulated cell therapies and affiliated technologies. For the purpose of this analysis, we considered those academic grants that have been awarded within this domain since 2013. In addition to highlighting key funding institutes, the chapter provides several emerging encapsulation methods, target indications, and type of cells, across which the majority of the research work is currently focused.
  • Chapter 12 features an insightful analysis, highlighting potential strategic partners (for instance, manufacturers) for encapsulated therapy developers, based on multiple parameters, such as therapeutic focus overlap, cell type overlap, research programs, existing collaborations, and developer strength. The analysis aims to provide the necessary inputs to the latter type of stakeholders, enabling them to make the right decisions to take their proprietary therapies/technologies from concept to the market with the help the appropriate partner entities.
  • Chapter 13 features a comprehensive market forecast, highlighting the future potential of this market until 2030 based on likely licensing deal structures and agreements that are expected to be signed in the foreseen future. In addition, we have provided information on (potential) sales-based revenues generated by encapsulated cell therapies that are currently in late stages of development for the treatment of different chronic disorders, based on parameters, such as target consumer segments, likely adoption rates, and expected pricing. The report features likely distribution of the current and forecasted opportunity across [A] different therapeutic areas (eye disorders, metabolic disorders, neurological disorders, and oncological disorders), [B] target disease indications (ataxia telangiectasia, breast cancer, diabetes, glaucoma, head and neck cancer, macular telangiectasia, pancreatic cancer, Parkinson's disease, and retinitis pigmentosa), [C] type of encapsulation material used (alginate-based microcapsules, cellulose hydrogels, medical-grade plastics, and red blood cells), and [D] key geographical regions (North America, Europe and Asia Pacific).
  • Chapter 14 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report and expressed our independent opinion related to the research and analysis described in the previous chapters.
  • Chapter 15 is a collection of executive insights of the discussions that were held with various key stakeholders in this market. The chapter provides a brief overview of the companies and details of interviews held with Alexander Scheer (Chief Scientific Officer, Erytech Pharma), Manuel Pires (Business Developer, Defymed), Michel Revel (Chief Scientist, Kadimastem) and Galit Mazooz-Perlmuter (Business Development Manager, Kadimastem), Mick McLean (Chief Executive Officer, Atelerix), Quinton Oswald (Former President and Chief Executive Officer, Neurotech Pharmaceuticals), William L Rust (Founder and Chief Executive Officer, Seraxis), and Yuval Avni (Former Chief Executive Officer, Beta-O2 Technologies).
  • Chapter 16 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.
  • Chapter 17 is an appendix, which provides the list of companies and organizations mentioned in the report.
Note: Product cover images may vary from those shown
5 of 5
  • 24Haymarket
  • 3P Biopharmaceuticals
  • 4D Pharma
  • Aarhus University Hospital
  • Acer Therapeutics
  • Activartis Biotech
  • Activate Immunotherapy
  • Adaptimmune
  • Adicet Bio
  • ADIRA
  • Aduro Biotech
  • Advent Bioservices
  • Agency for Science, Technology and Research
  • AgenTus Therapeutics
  • Aldagen
  • Allele Biotechnology & Pharmaceuticals
  • Alliance for Regenerative Medicine
  • Allife Medical Science and Technology
  • Allogene Therapeutics
  • Alsace BioValley
  • Altor BioScience
  • ALTuCELL
  • AlzeCure Pharma
  • Amgen
  • Amphera
  • AMVALOR
  • Anhui Kedgene Biotechnology
  • ANI Pharmaceuticals
  • Anterogen
  • apceth Biopharma
  • Arbele
  • ARCH Venture Partners
  • Argos Therapeutics
  • Asahi Glass Company
  • ASAP Ventures
  • Asset Management Partners
  • Astellas Institute for Regenerative Medicine
  • Astellas Pharma
  • Asterias Biotherapeutics
  • AstraZeneca
  • Atara Biotherapeutics
  • Atelerix
  • Athersys
  • Atlanpole
  • Atlantic Bio GMP
  • Atreca
  • Aurora Biopharma
  • Australian Foundation for Diabetes Research
  • Austrianova Singapore
  • Autolus
  • AVAX Technologies
  • Axil Scientific
  • Azellon Cell Therapeutics
  • Bain Capital Life Sciences
  • Bascom Palmer Eye Institute
  • Basic Pharma
  • Batavia Bioservices
  • Bavarian Nordic
  • Baxalta
  • Baxter International
  • Baylor College of Medicine
  • BBS Nanotechnology
  • Beijing Biohealthcare Biotechnology
  • Beijing Doing Biomedical
  • Beijing Immunochina Medical Science & Technology
  • Beijing Sanwater Biological Technology
  • Beijing Tricision Biotherapeutics
  • Beike Biotechnology
  • Bell Biosystems
  • Bellicum Pharmaceuticals
  • Beta-Cell
  • Beta-O2 Technologies
  • Betalin Therapeutics
  • Beyond Type 1
  • Bio Elpida
  • BioAtla
  • BioCardia
  • Bioencapsulation Research Group
  • Bioglex
  • Bioinova
  • Bioinspired Solutions
  • BioLamina
  • Bioneer
  • BioNTech
  • Biopredic
  • BioRestorative Therapies
  • BioTalentum
  • BIOTECanada
  • Biotechnology Innovation Organization
  • bluebird bio
  • Bone Therapeutics
  • Bpifrance
  • Brainstorm Cell Therapeutics
  • Brammer Bio
  • Brigham and Women's Hospital
  • Bristol-Myers Squibb
  • Broad Institute
  • Brown University
  • Caladrius Biosciences
  • California Institute for Regenerative Medicine
  • Calvert Crossland
  • Cambridge Enterprise
  • Capella Science
  • Capricor Therapeutics
  • Capsulæ
  • Captain T Cell
  • CardioCell
  • Carina Biotech
  • CARsgen Therapeutics
  • Cartherics
  • Casa Sollievo della Sofferenza
  • Case Western Reserve University
  • CBD Solutions
  • Celgene
  • Celixir
  • Cell and Gene Therapy Catapult
  • Cell Biotech
  • Cell Cure Neurosciences
  • Cell Genesys
  • Cell Medica
  • Cell Tech Pharmed
  • Cellectis
  • CellforCure
  • Cellin Technologies
  • CELLINK
  • CellMed Health
  • CellPraxis Bioengeneering
  • CellProtect Biotechnology
  • CellProtect Nordic Pharmaceuticals
  • CellProthera
  • Cells for Cells
  • Cellular Biomedicine Group
  • Cellular Dynamics International
  • Cellular Therapeutics
  • Celularity
  • Celyad
  • Censo Biotechnologies
  • Centre for Brain Research at the University of Auckland
  • Centre for Cell and Gene Processing
  • Centre for Commercialization of Regenerative Medicine
  • Cesca Therapeutics
  • Chamow & Associates
  • Chardan Capital Markets
  • Chengdu MedGenCell
  • Children's Hospital of Philadelphia
  • Children's Medical Center
  • CiMaas
  • Clinical Network Services
  • Cognate Bioservices
  • Conkwest
  • Cook Myosite
  • Corestem
  • Cornell University
  • Covance
  • Cowen Healthcare Investments
  • CRISPR Therapeutics
  • CRMI
  • Cryosite
  • CTI Clinical Trial and Consulting Services
  • Cytopeutics
  • Cytori Therapeutics
  • Cytosen Therapeutics
  • CytoSolv
  • Cytovac
  • CyTuVax
  • Daiichi Sankyo
  • Dana-Farber Cancer Institute
  • DanDrit Biotech
  • DCPrime
  • Defymed
  • Delta-Vir
  • Dendreon
  • DePuy Synthes
  • Diatranz Otsuka
  • DiscGenics
  • Dolomite Microfluidics
  • Duke-NUS Medical School
  • Durham University
  • East West Capital Partners
  • Ecomeris
  • Eight Roads Ventures
  • Eli Lilly
  • Elios Therapeutics
  • EMMES
  • Emory University
  • Encellin
  • Endocyte
  • Epigem
  • EryDel
  • Erytech Pharma
  • Ethicon
  • Eunice Kennedy Shriver National Institute of Child Health & Human Development
  • Eureka Therapeutics
  • European Foundation for the Study of Diabetes
  • Eutilex
  • Evotec
  • Exostem Biotec
  • Exploit Technologies
  • F-Prime Capital
  • F1 Oncology
  • Facet Life Sciences
  • Fate Therapeutics
  • Ferrer Internacional
  • Fibrocell Technologies
  • Fisher BioServices
  • Five Prime Therapeutics
  • Flagship Pioneering
  • Focus Gestioni
  • Formula Pharmaceuticals
  • Fortress Biotech
  • Fox Chase Cancer Center
  • French National Institute of Health and Medical Research
  • FronTier Merchant Capital
  • Gabriel Investments
  • Gadeta
  • Gamida Cell
  • GC Cell
  • Genentech
  • Genextra
  • Genzyme
  • Georgia Institute of Technology
  • GigaGen
  • Giner Labs
  • GlaxoSmithKline
  • Global Cell Med
  • Gloriana Therapeutics
  • Glycostem Therapeutics
  • Gradalis
  • Graybug Vision
  • Green Cross
  • Greenwood Way Capital
  • GRI Bio
  • Guangzhou Trinomab Biotech
  • H2M Capital
  • Harvard Stem Cell Institute
  • Heat Biologics
  • Hebei Senlang Biotechnology
  • Hebrew University of Jerusalem
  • Hemostemix
  • HengRui YuanZheng Bio-Technology
  • Histocell
  • Histogenics
  • Hitachi Chemical Advanced Therapeutics Solutions
  • Holostem Terapieavanzate
  • Howard Hughes Medical Institute
  • Hunan Zhaotai Yongren Biotech
  • I&L Biosystems
  • iCarTAB BioMed
  • iCell Gene Therapeutics
  • Imaging Endpoints
  • Immatics
  • Immetacyte
  • Immune Therapeutics
  • Immunicum
  • ImmunoCellular Therapeutics
  • Immunocore
  • Immunovative Therapies
  • Immutep
  • IMpacting Research, INnovation and Technology
  • ImStem Biotechnology
  • Imvax
  • iNanoBIT
  • Incysus
  • Inno Biologics
  • Innogest Capital
  • Innovative Cellular Therapeutics
  • Inovio Pharmaceuticals
  • inRegen
  • Institute for Basic Sciences
  • Institute of Virology at the University of Veterinary Medicine
  • Intellia Therapeutics
  • Intrexon
  • Iovance Biotherapeutics
  • Iowa State University
  • IRCAD France
  • Israel Innovation Authority
  • Isto Biologics
  • iThera Medical
  • Ivy Life Sciences
  • Janssen Biotech
  • Japan Tissue Engineering
  • JDRF
  • Jean Lamour Institute
  • Johns Hopkins University
  • Johnson & Johnson
  • Joslin Diabetes Center
  • Juno Therapeutics
  • Juvenile Diabetes Research Foundation
  • JW Biotechnology
  • JW CreaGene
  • Kadimastem
  • Kangstem Biotech
  • Kangwon National University
  • Karolinska Institutet
  • KBI Biopharma
  • King's College London
  • Kiromic
  • Kite Pharma
  • KTH Royal Institute of Technology
  • Legend Biotech
  • Leland Stanford Junior University
  • Leucid Bio
  • Lifecells
  • Likarda
  • Lincoln Park Capital Fund
  • Lion TCR
  • Living Cell Technologies
  • Living Pharma
  • Longeveron
  • Lonza
  • Lowy Medical Research Institute
  • Ludwig Maximilian University of Munich
  • Lund University
  • LV Prasad Eye Institute
  • Léon Bérard Center
  • Maine Medical Center
  • Marino Biotechnology
  • Marker Therapeutics
  • Maryland Technology Development
  • Massachusetts General Hospital
  • Massachusetts Institute of Technology
  • MaSTherCell
  • MaxCyte
  • MaxiVAX
  • Mayo Clinic
  • McGill University
  • MED-EL
  • Medeor Therapeutics
  • Medical University of South Carolina
  • Medicyte
  • MediGene
  • MedImmune
  • MEDINET
  • Medipost
  • Mediso
  • Medpace
  • Medtronic
  • MedVax Technologies
  • Medytox
  • Merck Serono
  • Mesoblast
  • Michael J Fox Foundation for Parkinson’s Research
  • MicroMecha
  • Miltenyi Biotec
  • Minovia Therapeutics
  • Moderna Therapeutics
  • MolecuVax
  • MolMed
  • Moraga Biotechnology
  • MPM Capital
  • Multimmune
  • Mustang Bio
  • Nantes-Atlantic National College of Veterinary Medicine, Food Science and Engineering
  • NantKwest
  • National Cancer Institute
  • National Center for Advancing Translational Sciences
  • National Council of Science and Technology, Mexico
  • National Eye Institute
  • National Heart, Lung, and Blood Institute
  • National Institute of Agricultural Research
  • National Institute of Allergy and Infectious Diseases
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases
  • National Institute of Biomedical Imaging and Bioengineering
  • National Institute of Dental and Craniofacial Research
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Institute of General Medical Sciences
  • National Institute of Neurological Disorders and Stroke
  • National Institute of Rehabilitation Training and Research
  • National Institute on Aging
  • National Institute on Deafness and Other Communication Disorders
  • National Institutes of Health
  • National Institutes of Health Clinical Center
  • National Research Council of Canada
  • National Science Foundation
  • Nemours Alfred I duPont Hospital for Children
  • Neopharm
  • Network IR
  • Neuralstem
  • Neurotech Pharmaceuticals
  • New York Blood Center
  • Newable Private Investing
  • Newcastle University
  • NewLink Genetics
  • Nikon CeLL innovation
  • Nimesis Technology
  • Nkarta Therapeutics
  • Nohla Therapeutics
  • Noile-Immune Biotech
  • Northeastern University
  • Northern Therapeutics
  • Northwest Biotherapeutics
  • Novadip Biosciences
  • NovaMatrix
  • Novartis
  • Novella Clinical
  • Noveome Biotherapeutics
  • Novo Nordisk
  • Novoron Bioscience
  • NSF Engineering Research Center for Cell Manufacturing Technologies
  • Nuffield Department of Surgical Sciences at the Oxford University
  • Ohio State University
  • OhioHealth
  • OiDE BetaRevive
  • Omega Ophthalmics
  • OncoBioMed
  • Oncodesign
  • One Cell Systems
  • OneVax
  • Ontario Institute for Regenerative Medicine
  • Opexa Therapeutics
  • Ophysio
  • OptoRobotix
  • Orchard Therapeutics
  • Oregon Health and Science University
  • Orphan Technologies
  • Osiris Therapeutics
  • Otsuka Pharmaceutical Factory
  • Oxford BioMedica
  • Oxford Technology Management
  • Parkwalk Advisors
  • Paul Langerhans Institut Dresden
  • PCI Services
  • PDC*line Pharma
  • Peak Capital Advisors
  • PersonGen BioTherapeutics
  • Pfizer
  • PharmaBio
  • PharmaCell
  • PharmaCyte Biotech
  • Pharmicell
  • Philadelphia VA Medical Center
  • Philips Healthcare
  • Pinze Lifetechnology
  • Pique Therapeutics
  • PL BioScience
  • Pluristem Therapeutics
  • Poseida Therapeutics
  • Praxis Pharmaceutical
  • Precision BioSciences
  • Pregene (ShenZhen) Biotechnology
  • Profusa
  • Promethera Biosciences
  • Providence Investments
  • Queen’s University
  • RA Capital Management
  • Ramcon
  • Ramot
  • Regeneris Medical
  • Regeneron
  • Regeneus
  • Regenics
  • ReNeuron
  • RHEACELL
  • Rice University
  • Roger Williams Medical Center
  • Roslin Cells
  • Rubius Therapeutics
  • Sanderling Ventures
  • Sanofi
  • Saronic Biotechnology
  • Scientist.com
  • Sclnow Biotechnology
  • Scottish Investment Bank
  • Seattle Genetics
  • SEMIA
  • Semma Therapeutics
  • Sentien Biotechnologies
  • Seraxis
  • Sernova
  • Servier
  • Shanghai Bioray Laboratory
  • Shanghai GeneChem
  • Shanghai Houchao Biotechnology
  • Shanghai iCELL Biotechnology
  • Shanghai Longyao Biotechnology
  • Shanghai Unicar-Therapy Bio-medicine Technology
  • Shenzhen BinDeBio
  • Shenzhen Hornetcorn Biotechnology
  • Sherpa InnoVentures
  • Shionogi
  • Sidney Kimmel Cancer Center
  • Sigilon Therapeutics
  • Sigma-Aldrich
  • Single Cell Technology
  • Sinobioway Cell Therapy
  • Skanderbeg Capital Advisors
  • SMT Bio
  • Sofinnova Partners
  • Sorrento Therapeutics
  • Sotio
  • Sphere Fluidics
  • SpherIngenics
  • SQZ Biotechnologies
  • Stanford University
  • Statistecol Consultants
  • Stem Cell Arabia
  • StemBios Technologies
  • STEMCELL Technologies
  • Stemedica Cell Technologies
  • Stempeutics Research
  • Super-T Cell Cancer
  • Surface Oncology
  • Swiss Cancer League
  • Swiss Group for Clinical Cancer Research
  • Sylvatica Biotech
  • SymbioCellTech
  • Symbiose Biomaterials
  • Tactiva Therapeutics
  • Taiwan Bio Therapeutics
  • Takara Bio
  • Takeda Pharmaceutical
  • Targazyme
  • TC BioPharm
  • TCR2 Therapeutics
  • Technocampus Group
  • Tella
  • Terumo
  • Tessa Therapeutics
  • Teva Pharmaceutical
  • TheraCyte
  • Thermo Fisher Scientific
  • Thomas Jefferson University
  • Tianhe Stem Cell Biotechnologies
  • Tianjin Ever Union Biotechnology
  • TiGenix
  • TILT Biotherapeutics
  • Tmunity Therapeutics
  • TNK Therapeutics
  • TotipotentRX
  • TPG Capital
  • TRACT Therapeutics
  • TransCure BioServices
  • Translational Drug Development
  • Trinity College Dublin
  • Triumvira Immunologics
  • Tufts University
  • Tulane University
  • TVAX Biomedical
  • TxCell
  • United States Department of Veterans Affairs
  • Universal Cells
  • University Health Network
  • University of Alabama, Birmingham
  • University of Alberta
  • University of Arizona
  • University of British Columbia
  • University of California
  • University of Cambridge
  • University of Chicago
  • University of Connecticut
  • University of Delaware
  • University of Florida
  • University of Life Sciences, Lublin
  • University of Lorraine
  • University of Los Andes
  • University of Louvain
  • University of Massachusetts Medical School
  • University of Miami
  • University of Michigan
  • University of North Carolina
  • University of Northern Colorado
  • University of Pennsylvania
  • University of Perugia
  • University of Pittsburgh
  • University of Rochester
  • University of Strathclyde
  • University of Texas Southwestern Medical Center
  • University of Veterinary Medicine, Vienna
  • University of Virginia
  • University of Wisconsin Madison
  • University of Zurich
  • Unum Therapeutics
  • Uppsala University Hospital
  • US Department of Defense
  • US Stem Cell
  • UZ Brussel
  • UZ Leuven
  • Vaccinogen
  • Valorial
  • Vanderbilt University Medical Center
  • VEGEPOLYS
  • Vericel
  • ViaCyte
  • ViCapsys
  • ViroMed
  • ViruSure
  • Viscofan BioEngineering
  • Vissum
  • Vor Biopharma
  • W L Gore & Associates
  • Waisman Biomanufacturing
  • Wake Forest School of Medicine
  • Werth Family Investment Associates
  • Whitehead Institute for Biomedical Research
  • WiSP Wissenschaftlicher Service Pharma
  • Wuhan Sian Medical Technology
  • Wuxi AppTec
  • Wyss Institute for Biologically Inspired Engineering
  • Xcelthera
  • Xellbiogene
  • XEME Biopharma
  • YposKesi
  • Zelluna Immunotherapy
  • Zhongguancun Lianchuang Medical Engineering Transformation Center
  • Zimmer Biomet
  • ZIOPHARM Oncology
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4770787
Adroll
adroll